<?xml version="1.0" encoding="utf-8"?><Survey ProjectId="p230052930" TargetLanguage="11274" BaseLanguage="9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://www.confirmit.com/TranslationXmlSchema.xsd"><Checksum>1C2D956775CB99B2E3C2B1C4A946EA34</Checksum><Routing><Folder ObjectId="(0:0-230052943#609425368, 198)" Name="WorldOne userid for pass back to client"><Nodes><Open ObjectId="(0:0-230052950#609425386, 164)" Name="P"></Open><Open ObjectId="(0:0-230052962#609425412, 164)" Name="r0"></Open></Nodes></Folder><Folder ObjectId="(0:0-230052973#609425436, 198)" Name="Screener"><Nodes><Single ObjectId="(0:0-230052976#609425444, 164)" Name="Sq1"><Title LanguageId="11274">Sq1</Title><Text LanguageId="11274">In what country is your practice located?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230052986#609425470, 207)" Precode="1"><Text LanguageId="11274">Mexico</Text></Answer><Answer ObjectId="(0:0-230052987#609425475, 207)" Precode="2"><Text LanguageId="11274">Argentina</Text></Answer><Answer ObjectId="(0:0-230052988#609425480, 207)" Precode="98"><Text LanguageId="11274">Other</Text></Answer></Answers></Single><Single ObjectId="(0:0-230053012#609425542, 164)" Name="Sq2"><Title LanguageId="11274">Sq2</Title><Text LanguageId="11274">What is your specialty?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230053022#609425567, 207)" Precode="1"><Text LanguageId="11274">Oncologist/Medical Oncologist</Text></Answer><Answer ObjectId="(0:0-230053023#609425572, 207)" Precode="98"><Text LanguageId="11274">Other (including surgeon oncologist)</Text></Answer></Answers></Single><Multi ObjectId="(0:0-230053040#611774749, 164)" Name="Sq3"><Title LanguageId="11274">Sq3</Title><Text LanguageId="11274">How many adult patients with the following conditions do you typically treat per month?</Text><Instruction LanguageId="11274">Enter a whole number for each row.</Instruction><Answers><Answer ObjectId="(0:0-230053050#611774778, 207)" Precode="1"><Text LanguageId="11274">Breast cancer (CaB)</Text></Answer><Answer ObjectId="(0:0-230053051#611774783, 207)" Precode="2"><Text LanguageId="11274">Advanced/metastatic Non-small cell lung cancer (NSCLC)</Text></Answer><Answer ObjectId="(0:0-230053052#611774788, 207)" Precode="3"><Text LanguageId="11274">Metastatic Colorectal cancer (mCRC)</Text></Answer><Answer ObjectId="(0:0-230053053#611774793, 207)" Precode="4"><Text LanguageId="11274">Unresectable or metastatic Malignant Melanoma</Text></Answer></Answers></Multi><Page ObjectId="(0:0-230053074#611774853, 182)" Name="Page49"><Nodes><Info ObjectId="(0:0-230053076#611774859, 164)" Name="Sq4"><Title LanguageId="11274">Sq4</Title><Text LanguageId="11274">Which of the following targeted therapies do you currently prescribe for the following conditions outside of a clinical trial?</Text></Info><Multi ObjectId="(0:0-230053087#611774886, 164)" Name="Sq4a"><Title LanguageId="11274">Sq4a</Title><Text LanguageId="11274">CaB</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230053097#611774912, 207)" Precode="1"><Text LanguageId="11274">Herceptin (trastuzumab)</Text></Answer><Answer ObjectId="(0:0-230053098#611774917, 207)" Precode="2"><Text LanguageId="11274">Kadcyla (ado-trastuzumab emtansine)</Text></Answer><Answer ObjectId="(0:0-230053099#611774922, 207)" Precode="3"><Text LanguageId="11274">Perjeta (pertuzumab)</Text></Answer><Answer ObjectId="(0:0-230053100#611774927, 207)" Precode="4"><Text LanguageId="11274">Tykerb (lapatinib)</Text></Answer><Answer ObjectId="(0:0-230053101#611774932, 207)" Precode="99"><Text LanguageId="11274">None of the above</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230053118#611774973, 164)" Name="Sq4b"><Title LanguageId="11274">Sq4b</Title><Text LanguageId="11274">Advanced/metastatic NSCLC</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230053128#611774999, 207)" Precode="1"><Text LanguageId="11274">Erbitux (cetuximab)</Text></Answer><Answer ObjectId="(0:0-230053129#611775004, 207)" Precode="2"><Text LanguageId="11274">Giotrif/Gilotrif (afatinib)</Text></Answer><Answer ObjectId="(0:0-230053130#611775009, 207)" Precode="3"><Text LanguageId="11274">Iressa (gefitinib)</Text></Answer><Answer ObjectId="(0:0-230053131#611775014, 207)" Precode="4"><Text LanguageId="11274">Tarceva (erlotinib)</Text></Answer><Answer ObjectId="(0:0-230053132#611775019, 207)" Precode="5"><Text LanguageId="11274">Xalkori (crizotinib)</Text></Answer><Answer ObjectId="(0:0-230053133#611775024, 207)" Precode="99"><Text LanguageId="11274">None of the above</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230053152#611704413, 164)" Name="Sq4c"><Title LanguageId="11274">Sq4c</Title><Text LanguageId="11274">mCRC</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230053162#611704439, 207)" Precode="1"><Text LanguageId="11274">Erbitux (cetuximab)</Text></Answer><Answer ObjectId="(0:0-230053163#611704444, 207)" Precode="2"><Text LanguageId="11274">Vectibix (panitumumab)</Text></Answer><Answer ObjectId="(0:0-230053164#611704449, 207)" Precode="99"><Text LanguageId="11274">None of the above</Text></Answer></Answers></Multi><Single ObjectId="(0:0-230053177#611704480, 164)" Name="Sq4d"><Title LanguageId="11274">Sq4d</Title><Text LanguageId="11274">Zelboraf (vemurafenib)</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230053187#611704505, 207)" Precode="1"><Text LanguageId="11274">Yes</Text></Answer><Answer ObjectId="(0:0-230053188#611704510, 207)" Precode="99"><Text LanguageId="11274">No</Text></Answer></Answers></Single></Nodes></Page><Open ObjectId="(0:0-230053212#611704575, 164)" Name="Sq5"><Title LanguageId="11274">Sq5</Title><Text LanguageId="11274">How many years have you practiced since qualifying as an oncologist?</Text><Instruction LanguageId="11274">Enter a whole number of years.</Instruction></Open><Single ObjectId="(0:0-230053230#611704624, 164)" Name="Sq6"><Title LanguageId="11274">Sq6</Title><Text LanguageId="11274">How would you best describe the setting(s) in which you practice?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230053240#611704650, 207)" Precode="1"><Text LanguageId="11274">Public setting only</Text></Answer><Answer ObjectId="(0:0-230053241#611704655, 207)" Precode="2"><Text LanguageId="11274">Private setting only</Text></Answer><Answer ObjectId="(0:0-230053242#611704660, 207)" Precode="3"><Text LanguageId="11274">I work in both settings</Text></Answer></Answers></Single><Grid3D ObjectId="(0:0-230053266#611756181, 204)" Name="Sq7"><Title LanguageId="11274">Sq7</Title><Text LanguageId="11274">Among the patients with &lt;u&gt;Cab, NSCLC, CRC and MM&lt;/u&gt; you treat per month, what percentage are public vs private patients?&lt;/p&gt;&lt;p&gt;^f('Sq1').get() == '1' ? &quot;We define ‘public patients’ as patients that are dependent upon Social Security (IMSS, ISSSTE) or government sponsorship (e.g. Seguro Popular) of treatments.  &lt;br&gt;&lt;br&gt;We define ‘private patients’ as patients who have supplementary private insurance.&quot; : &quot;We define ‘public patients’ as patients that are dependent upon Social Security (Obras Sociales, PAMI) or government sponsorship (e.g. Remediar + Redes) of treatments.  &lt;br&gt;&lt;br&gt;We define ‘private patients’ as patients who have supplementary private insurance (through Obras Sociales privadas or Empresas de Medicina Prepaga).&quot;^&lt;/p&gt;</Text><Instruction LanguageId="11274">Enter whole percentages for each column. Totals must sum to 100%.</Instruction><Answers><Answer ObjectId="(0:0-230053342#611756486, 207)" Precode="1"><Text LanguageId="11274">Public patients</Text></Answer><Answer ObjectId="(0:0-230053343#611756491, 207)" Precode="2"><Text LanguageId="11274">Private patients</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053268#611756189, 164)" Name="Sq7_a"><Title LanguageId="11274">Sq7_a</Title><Text LanguageId="11274">% of CaB patients</Text></Multi><Multi ObjectId="(0:0-230053284#611756261, 164)" Name="Sq7_b"><Title LanguageId="11274">Sq7_b</Title><Text LanguageId="11274">% of advanced/metastatic NSCLC patients</Text></Multi><Multi ObjectId="(0:0-230053300#611756321, 164)" Name="Sq7_c"><Title LanguageId="11274">Sq7_c</Title><Text LanguageId="11274">% of mCRC patients</Text></Multi><Multi ObjectId="(0:0-230053316#611756381, 164)" Name="Sq7_d"><Title LanguageId="11274">Sq7_d</Title><Text LanguageId="11274">% of unresectable or metastatic Malignant Melanoma patients</Text></Multi></Nodes></Grid3D><Single ObjectId="(0:0-230053356#611765265, 164)" Name="Sq8a"><Title LanguageId="11274">Sq8a</Title><Text LanguageId="11274">In what city is your practice located?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230053366#611765291, 207)" Precode="1"><Text LanguageId="11274">Mexico City</Text></Answer><Answer ObjectId="(0:0-230053367#611765296, 207)" Precode="2"><Text LanguageId="11274">Guadalajara</Text></Answer><Answer ObjectId="(0:0-230053368#611765301, 207)" Precode="3"><Text LanguageId="11274">Monterrey</Text></Answer><Answer ObjectId="(0:0-230053369#611765306, 207)" Precode="4"><Text LanguageId="11274">Puebla</Text></Answer><Answer ObjectId="(0:0-230053370#611765311, 207)" Precode="5"><Text LanguageId="11274">Merida</Text></Answer><Answer ObjectId="(0:0-230053371#611765316, 207)" Precode="6"><Text LanguageId="11274">Xalapa</Text></Answer><Answer ObjectId="(0:0-230053372#611765321, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Single><Single ObjectId="(0:0-230053401#611765389, 164)" Name="Sq8b"><Title LanguageId="11274">Sq8b</Title><Text LanguageId="11274">In what city is your practice located?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230053411#611765415, 207)" Precode="1"><Text LanguageId="11274">Buenos Aires</Text></Answer><Answer ObjectId="(0:0-230053412#611765420, 207)" Precode="2"><Text LanguageId="11274">San Justo</Text></Answer><Answer ObjectId="(0:0-230053413#611765425, 207)" Precode="3"><Text LanguageId="11274">Cordoba</Text></Answer><Answer ObjectId="(0:0-230053414#611765430, 207)" Precode="4"><Text LanguageId="11274">Rosario</Text></Answer><Answer ObjectId="(0:0-230053415#611765435, 207)" Precode="5"><Text LanguageId="11274">Mendoza</Text></Answer><Answer ObjectId="(0:0-230053416#611765440, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Single><Multi ObjectId="(0:0-230053443#611765510, 164)" Name="Sq9"><Title LanguageId="11274">Sq9</Title><Text LanguageId="11274">What is your hospital/clinic type?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230053453#611765549, 207)" Precode="1"><Text LanguageId="11274">Medium complexity (secondary care) public hospital</Text></Answer><Answer ObjectId="(0:0-230053454#611765554, 207)" Precode="2"><Text LanguageId="11274">High complexity (tertiary care) public hospital</Text></Answer><Answer ObjectId="(0:0-230053455#611765559, 207)" Precode="3"><Text LanguageId="11274">Research-based/university hospital</Text></Answer><Answer ObjectId="(0:0-230053456#611765564, 207)" Precode="4"><Text LanguageId="11274">Private affiliated with public programs</Text></Answer><Answer ObjectId="(0:0-230053457#611765569, 207)" Precode="5"><Text LanguageId="11274">Private &lt;u&gt;not&lt;/u&gt; affiliated with public programs</Text></Answer><Answer ObjectId="(0:0-230053458#611765574, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Single ObjectId="(0:0-230053480#611772309, 164)" Name="Sq10"><Title LanguageId="11274">Sq10</Title><Text LanguageId="11274">What is your public hospital affiliation?</Text><Instruction LanguageId="11274">Please select one.</Instruction><Answers><Answer ObjectId="(0:0-230053490#611772335, 207)" Precode="1"><Text LanguageId="11274">Social Security – IMSS</Text></Answer><Answer ObjectId="(0:0-230053491#611772340, 207)" Precode="2"><Text LanguageId="11274">Social Security – ISSSTE</Text></Answer><Answer ObjectId="(0:0-230053492#611772345, 207)" Precode="3"><Text LanguageId="11274">Social Security – Other (please specify)</Text></Answer><Answer ObjectId="(0:0-230053493#611772350, 207)" Precode="4"><Text LanguageId="11274">Ministry of Health/Secretaria de Salud (SSA) – Seguro Popular (SP)</Text></Answer><Answer ObjectId="(0:0-230053494#611772355, 207)" Precode="5"><Text LanguageId="11274">SSA – Other (please specify)</Text></Answer><Answer ObjectId="(0:0-230053495#611772360, 207)" Precode="98"><Text LanguageId="11274">Other</Text></Answer></Answers></Single></Nodes></Folder><Folder ObjectId="(0:0-230053522#611772429, 198)" Name="Main"><Nodes><Info ObjectId="(0:0-230053524#611772434, 164)" Name="info12"><Title LanguageId="11274">info12</Title><Text LanguageId="11274">Please bear in mind that throughout this survey only your patients &lt;u&gt;outside clinical trials and outside Best Supportive Care/palliative care&lt;/u&gt; will be considered.</Text></Info><Grid3D ObjectId="(0:0-230053538#611772485, 204)" Name="q1BM"><Title LanguageId="11274">q1BM</Title><Text LanguageId="11274">What percentage of your diagnosed patients with the following conditions receive any active treatment (i.e. chemotherapy/targeted therapy)?</Text><Instruction LanguageId="11274">Enter whole percentages for each answer.</Instruction><Answers><Answer ObjectId="(0:0-230053582#611762987, 207)" Precode="1"><Text LanguageId="11274">Breast cancer (CaB)</Text></Answer><Answer ObjectId="(0:0-230053583#611762992, 207)" Precode="2"><Text LanguageId="11274">Advanced/metastatic Non-small cell lung cancer (NSCLC)</Text></Answer><Answer ObjectId="(0:0-230053584#611762997, 207)" Precode="3"><Text LanguageId="11274">Metastatic Colorectal cancer (mCRC)</Text></Answer><Answer ObjectId="(0:0-230053585#611763002, 207)" Precode="4"><Text LanguageId="11274">Unresectable or metastatic Malignant Melanoma</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053540#611772490, 164)" Name="q1aBM"><Title LanguageId="11274">q1aBM</Title><Text LanguageId="11274">% of public patients</Text></Multi><Multi ObjectId="(0:0-230053556#611772581, 164)" Name="q1bBM"><Title LanguageId="11274">q1bBM</Title><Text LanguageId="11274">% of private patients</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230053599#611763038, 204)" Name="q2aBM"><Title LanguageId="11274">q2aBM</Title><Text LanguageId="11274">Which of the following targeted therapies are included on each of the formularies listed with indication for:

&lt;br&gt;&lt;br&gt;&lt;u&gt;CaB&lt;/u&gt;</Text><Instruction LanguageId="11274">Select all that apply. Note, if a drug is included for another indication in your formulary besides the indication listed, please do not select it.</Instruction><Answers><Answer ObjectId="(0:0-230053659#611763189, 207)" Precode="1"><Text LanguageId="11274">Herceptin (trastuzumab)</Text></Answer><Answer ObjectId="(0:0-230053660#611763194, 207)" Precode="2"><Text LanguageId="11274">Kadcyla (ado-trastuzumab emtansine)</Text></Answer><Answer ObjectId="(0:0-230053661#611763199, 207)" Precode="3"><Text LanguageId="11274">Perjeta (pertuzumab)</Text></Answer><Answer ObjectId="(0:0-230053662#611763204, 207)" Precode="4"><Text LanguageId="11274">Tykerb (lapatinib)</Text></Answer><Answer ObjectId="(0:0-230053663#611763209, 207)" Precode="5"><Text LanguageId="11274">Avastin (bevacizumab)</Text></Answer><Answer ObjectId="(0:0-230053664#611763214, 207)" Precode="99"><Text LanguageId="11274">None of these</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053601#611763045, 164)" Name="q2aBM_a"><Title LanguageId="11274">q2aBM_a</Title><Text LanguageId="11274">Public setting: &lt;br&gt;Hospital/ institutional formulary</Text></Multi><Multi ObjectId="(0:0-230053617#611763084, 164)" Name="q2aBM_b"><Title LanguageId="11274">q2aBM_b</Title><Text LanguageId="11274">Public setting: ^f('Sq1').get() == '1' ? &quot;State&quot; : &quot;Province&quot;^ formulary&lt;br/&gt;</Text></Multi><Multi ObjectId="(0:0-230053633#611763124, 164)" Name="q2aBM_c"><Title LanguageId="11274">q2aBM_c</Title><Text LanguageId="11274">Private setting: &lt;br/&gt;Hospital/ institutional formulary&lt;br/&gt;</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230053682#579365831, 204)" Name="q2bBM"><Title LanguageId="11274">q2bBM</Title><Text LanguageId="11274">Which of the following targeted therapies are included on each of the formularies listed with indication for:

&lt;br&gt;&lt;br&gt;&lt;u&gt;NSCLC&lt;/u&gt;</Text><Instruction LanguageId="11274">Select all that apply. Note, if a drug is included for another indication in your formulary besides the indication listed, please do not select it.</Instruction><Answers><Answer ObjectId="(0:0-230053742#579365982, 207)" Precode="1"><Text LanguageId="11274">Erbitux (cetuximab)</Text></Answer><Answer ObjectId="(0:0-230053743#579365987, 207)" Precode="2"><Text LanguageId="11274">Gilotrif/Giotrif (afatinib)</Text></Answer><Answer ObjectId="(0:0-230053744#579365992, 207)" Precode="3"><Text LanguageId="11274">Iressa (gefitinib)</Text></Answer><Answer ObjectId="(0:0-230053745#579365997, 207)" Precode="4"><Text LanguageId="11274">Tarceva (erlotinib)</Text></Answer><Answer ObjectId="(0:0-230053746#579366002, 207)" Precode="5"><Text LanguageId="11274">Xalkori (crizotinib)</Text></Answer><Answer ObjectId="(0:0-230053747#579366007, 207)" Precode="6"><Text LanguageId="11274">Avastin (bevacizumab)</Text></Answer><Answer ObjectId="(0:0-230053748#579366012, 207)" Precode="99"><Text LanguageId="11274">None of these</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053684#579365838, 164)" Name="q2bBM_a"><Title LanguageId="11274">q2bBM_a</Title><Text LanguageId="11274">Public setting: &lt;br&gt;Hospital/ institutional formulary</Text></Multi><Multi ObjectId="(0:0-230053700#579365877, 164)" Name="q2bBM_b"><Title LanguageId="11274">q2bBM_b</Title><Text LanguageId="11274">Public setting: ^f('Sq1').get() == '1' ? &quot;State&quot; : &quot;Province&quot;^ formulary&lt;br/&gt;</Text></Multi><Multi ObjectId="(0:0-230053716#579365917, 164)" Name="q2bBM_c"><Title LanguageId="11274">q2bBM_c</Title><Text LanguageId="11274">Private setting: &lt;br/&gt;Hospital/ institutional formulary&lt;br/&gt;</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230053771#608015789, 204)" Name="q2cBM"><Title LanguageId="11274">q2cBM</Title><Text LanguageId="11274">Which of the following targeted therapies are included on each of the formularies listed with indication for:

&lt;br&gt;&lt;br&gt;&lt;u&gt;CRC&lt;/u&gt;</Text><Instruction LanguageId="11274">Select all that apply. Note, if a drug is included for another indication in your formulary besides the indication listed, please do not select it.</Instruction><Answers><Answer ObjectId="(0:0-230053831#608015941, 207)" Precode="1"><Text LanguageId="11274">Erbitux (cetuximab)</Text></Answer><Answer ObjectId="(0:0-230053832#608015946, 207)" Precode="2"><Text LanguageId="11274">Vectibix (panitumumab)</Text></Answer><Answer ObjectId="(0:0-230053833#608015951, 207)" Precode="3"><Text LanguageId="11274">Avastin (bevacizumab)</Text></Answer><Answer ObjectId="(0:0-230053834#608015956, 207)" Precode="4"><Text LanguageId="11274">Regorafenib (Stivarga)</Text></Answer><Answer ObjectId="(0:0-230053835#608015961, 207)" Precode="99"><Text LanguageId="11274">None of these</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053773#608015797, 164)" Name="q2cBM_a"><Title LanguageId="11274">q2cBM_a</Title><Text LanguageId="11274">Public setting: &lt;br&gt;Hospital/ institutional formulary</Text></Multi><Multi ObjectId="(0:0-230053789#608015836, 164)" Name="q2cBM_b"><Title LanguageId="11274">q2cBM_b</Title><Text LanguageId="11274">Public setting: ^f('Sq1').get() == '1' ? &quot;State&quot; : &quot;Province&quot;^ formulary&lt;br/&gt;</Text></Multi><Multi ObjectId="(0:0-230053805#608015876, 164)" Name="q2cBM_c"><Title LanguageId="11274">q2cBM_c</Title><Text LanguageId="11274">Private setting: &lt;br/&gt;Hospital/ institutional formulary&lt;br/&gt;</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230053851#608016004, 204)" Name="q2dBM"><Title LanguageId="11274">q2dBM</Title><Text LanguageId="11274">Which of the following targeted therapies are included on each of the formularies listed with indication for:

&lt;br&gt;&lt;br&gt;&lt;u&gt;Malignant Melanoma&lt;/u&gt;</Text><Instruction LanguageId="11274">Select all that apply. Note, if a drug is included for another indication in your formulary besides the indication listed, please do not select it.</Instruction><Answers><Answer ObjectId="(0:0-230053911#611455139, 207)" Precode="1"><Text LanguageId="11274">Zelboraf (vemurafenib)</Text></Answer><Answer ObjectId="(0:0-230053912#611455144, 207)" Precode="2"><Text LanguageId="11274">Yervoy (ipilimumab)</Text></Answer><Answer ObjectId="(0:0-230053913#611455149, 207)" Precode="99"><Text LanguageId="11274">None of these</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053853#608016009, 164)" Name="q2dBM_a"><Title LanguageId="11274">q2dBM_a</Title><Text LanguageId="11274">Public setting: &lt;br&gt;Hospital/ institutional formulary</Text></Multi><Multi ObjectId="(0:0-230053869#611455033, 164)" Name="q2dBM_b"><Title LanguageId="11274">q2dBM_b</Title><Text LanguageId="11274">Public setting: ^f('Sq1').get() == '1' ? &quot;State&quot; : &quot;Province&quot;^ formulary&lt;br/&gt;</Text></Multi><Multi ObjectId="(0:0-230053885#611455073, 164)" Name="q2dBM_c"><Title LanguageId="11274">q2dBM_c</Title><Text LanguageId="11274">Private setting: &lt;br/&gt;Hospital/ institutional formulary&lt;br/&gt;</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230053928#611455205, 204)" Name="q3BM"><Title LanguageId="11274">q3BM</Title><Text LanguageId="11274">What percentage of your patients with the following tumors whom you consider eligible for treatment with targeted therapies, does not receive it primarily because of cost, budgetary, or reimbursement reasons?

&lt;p&gt;&lt;p&gt;Please bear in mind that we are referring to the following treatments: 
&lt;p&gt;•	CaB (neoadjuvant, adjuvant and metastatic settings): Herceptin (trastuzumab); Kadcyla (ado-trastuzumab emtansine); Perjeta (pertuzumab); Tykerb (lapatinib)
&lt;p&gt;•	Advanced/metastatic NSCLC: Erbitux (cetuximab); Gilotrif/Giotrif (afatinib); Iressa (gefitinib); Tarceva (erlotinib); Xalkori (crizotinib)
&lt;p&gt;•	mCRC: Erbitux (cetuximab); Vectibix (panitumumab)
&lt;p&gt;•	Unresectable/metastatic Malignant Melanoma: Zelboraf (vemurafenib)</Text><Instruction LanguageId="11274">Enter whole percentages for each answer.</Instruction><Answers><Answer ObjectId="(0:0-230053972#611734305, 207)" Precode="1"><Text LanguageId="11274">CaB</Text></Answer><Answer ObjectId="(0:0-230053973#611734310, 207)" Precode="2"><Text LanguageId="11274">Advanced/metastatic NSCLC</Text></Answer><Answer ObjectId="(0:0-230053974#611734315, 207)" Precode="3"><Text LanguageId="11274">mCRC</Text></Answer><Answer ObjectId="(0:0-230053975#611734320, 207)" Precode="4"><Text LanguageId="11274">Unresectable/metastatic Malignant Melanoma</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053930#611455210, 164)" Name="q3aBM"><Title LanguageId="11274">q3aBM</Title><Text LanguageId="11274">% of public patients</Text></Multi><Multi ObjectId="(0:0-230053946#611455268, 164)" Name="q3bBM"><Title LanguageId="11274">q3bBM</Title><Text LanguageId="11274">% of private patients</Text></Multi></Nodes></Grid3D><Page ObjectId="(0:0-230053995#611734379, 182)" Name="Page50"><Nodes><Grid3D ObjectId="(0:0-230053997#611734384, 204)" Name="q4BM"><Title LanguageId="11274">q4BM</Title><Text LanguageId="11274">Which reimbursement or availability issues limit your prescribing of targeted therapies in eligible CaB, NSCLC, CRC and Malignant Melanoma patients?</Text><Instruction LanguageId="11274">Select all that apply per column.</Instruction><Answers><Answer ObjectId="(0:0-230054073#581277374, 207)" Precode="1"><Text LanguageId="11274">Lack of coverage from my institution</Text></Answer><Answer ObjectId="(0:0-230054074#581277379, 207)" Precode="2"><Text LanguageId="11274">Not included in the CByCM interinstitucional (national formulary)</Text></Answer><Answer ObjectId="(0:0-230054075#581277384, 207)" Precode="3"><Text LanguageId="11274">Not included in the institutional formularies (IMSS, ISSSTE, etc)</Text></Answer><Answer ObjectId="(0:0-230054076#581277389, 207)" Precode="4"><Text LanguageId="11274">Not included in Seguro Popular Formulary (FPcGC)</Text></Answer><Answer ObjectId="(0:0-230054077#581277394, 207)" Precode="5"><Text LanguageId="11274">Despite formulary listing, SS healthcare institution budget limits availability of targeted agents</Text></Answer><Answer ObjectId="(0:0-230054078#581277399, 207)" Precode="6"><Text LanguageId="11274">Despite SUR (Sistema Unico de Reintegro) formulary listing, most Obras Sociales budgets limit availability of targeted agents</Text></Answer><Answer ObjectId="(0:0-230054079#581277404, 207)" Precode="7"><Text LanguageId="11274">Budgetary restrictions at my hospital/clinic</Text></Answer><Answer ObjectId="(0:0-230054080#581277409, 207)" Precode="8"><Text LanguageId="11274">Patient cannot afford the out-of-pocket costs</Text></Answer><Answer ObjectId="(0:0-230054081#581277414, 207)" Precode="9"><Text LanguageId="11274">Patient does not fulfill all clinical criteria defined in treatment guidelines to targeted agents with public coverage (e.g. disease severity).</Text></Answer><Answer ObjectId="(0:0-230054082#581277419, 207)" Precode="10"><Text LanguageId="11274">Patient does not fulfill all clinical criteria defined in treatment guidelines to receive targeted agents with private coverage (e.g. disease severity)</Text></Answer><Answer ObjectId="(0:0-230054083#581277424, 207)" Precode="11"><Text LanguageId="11274">Patient does not fulfill all administrative/bureaucratic criteria to receive targeted drugs with public coverage</Text></Answer><Answer ObjectId="(0:0-230054084#581277429, 207)" Precode="12"><Text LanguageId="11274">Patient does not fulfill all administrative/bureaucratic criteria to receive targeted drugs with private coverage</Text></Answer><Answer ObjectId="(0:0-230054085#581277434, 207)" Precode="13"><Text LanguageId="11274">Patient cannot access centers to receive the drug (e.g. because centers are located too far away)</Text></Answer><Answer ObjectId="(0:0-230054086#581277439, 207)" Precode="14"><Text LanguageId="11274">Despite drug formulary listing, biomarkers tests are not covered in my institution</Text></Answer><Answer ObjectId="(0:0-230054087#581277444, 207)" Precode="98"><Text LanguageId="11274">Other</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230053999#611734389, 164)" Name="q4aBM"><Title LanguageId="11274">q4aBM</Title><Text LanguageId="11274">CaB</Text></Multi><Multi ObjectId="(0:0-230054015#611734426, 164)" Name="q4bBM"><Title LanguageId="11274">q4bBM</Title><Text LanguageId="11274">NSCLC</Text></Multi><Multi ObjectId="(0:0-230054031#611734463, 164)" Name="q4cBM"><Title LanguageId="11274">q4cBM</Title><Text LanguageId="11274">CRC</Text></Multi><Multi ObjectId="(0:0-230054047#611734500, 164)" Name="q4dBM"><Title LanguageId="11274">q4dBM</Title><Text LanguageId="11274">Malignant Melanoma</Text></Multi></Nodes></Grid3D><Open ObjectId="(0:0-230054123#581277559, 164)" Name="q4aBM_Other"><Title LanguageId="11274">q4aBM_Other</Title><Text LanguageId="11274">Please specify the Other for CaB.</Text></Open><Open ObjectId="(0:0-230054135#581277588, 164)" Name="q4bBM_Other"><Title LanguageId="11274">q4bBM_Other</Title><Text LanguageId="11274">Please specify the Other for NSCLC.</Text></Open><Open ObjectId="(0:0-230054147#581277617, 164)" Name="q4cBM_Other"><Title LanguageId="11274">q4cBM_Other</Title><Text LanguageId="11274">Please specify the Other for CRC.</Text></Open><Open ObjectId="(0:0-230054159#611750431, 164)" Name="q4dBM_Other"><Title LanguageId="11274">q4dBM_Other</Title><Text LanguageId="11274">Please specify the Other for Malignant Melanoma.</Text></Open></Nodes></Page><Grid ObjectId="(0:0-230054179#611750481, 164)" Name="q5BM"><Title LanguageId="11274">q5BM</Title><Text LanguageId="11274">Which of the following targeted therapies are typically reimbursed for your cancer patients under private health plans in the following treatment settings?</Text><Instruction LanguageId="11274">Select one per row.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230054192#611750523, 225)" Precode="h1"><Text LanguageId="11274">&lt;u&gt;CaB&lt;/u&gt;</Text></HeaderAnswer><Answer ObjectId="(0:0-230054193#611750525, 207)" Precode="1"><Text LanguageId="11274">Herceptin (trastuzumab)</Text></Answer><Answer ObjectId="(0:0-230054194#611750530, 207)" Precode="2"><Text LanguageId="11274">Tykerb (lapatinib)</Text></Answer><Answer ObjectId="(0:0-230054195#611750535, 207)" Precode="3"><Text LanguageId="11274">Perjeta (pertuzumab)</Text></Answer><Answer ObjectId="(0:0-230054196#611750540, 207)" Precode="4"><Text LanguageId="11274">Kadcyla (ado trastuzumab emtansine)</Text></Answer><Answer ObjectId="(0:0-230054197#611750545, 207)" Precode="5"><Text LanguageId="11274">Avastin (bevacizumab)</Text></Answer><HeaderAnswer ObjectId="(0:0-230054199#611750552, 225)" Precode="h2"><Text LanguageId="11274">&lt;u&gt;NSCLC&lt;/u&gt;</Text></HeaderAnswer><Answer ObjectId="(0:0-230054200#611750554, 207)" Precode="6"><Text LanguageId="11274">Erbitux (cetuximab)</Text></Answer><Answer ObjectId="(0:0-230054201#611750559, 207)" Precode="7"><Text LanguageId="11274">Gilotrif/Giotrif (afatinib)</Text></Answer><Answer ObjectId="(0:0-230054202#611750564, 207)" Precode="8"><Text LanguageId="11274">Iressa (gefitinib)</Text></Answer><Answer ObjectId="(0:0-230054203#611750569, 207)" Precode="9"><Text LanguageId="11274">Tarceva (erlotinib)</Text></Answer><Answer ObjectId="(0:0-230054204#611750574, 207)" Precode="10"><Text LanguageId="11274">Xalkori (crizotinib)</Text></Answer><Answer ObjectId="(0:0-230054205#611750579, 207)" Precode="11"><Text LanguageId="11274">Avastin (bevacizumab)</Text></Answer><HeaderAnswer ObjectId="(0:0-230054207#611750586, 225)" Precode="h3"><Text LanguageId="11274">&lt;u&gt;CRC&lt;/u&gt;</Text></HeaderAnswer><Answer ObjectId="(0:0-230054208#611750588, 207)" Precode="12"><Text LanguageId="11274">Erbitux (cetuximab)</Text></Answer><Answer ObjectId="(0:0-230054209#611750593, 207)" Precode="13"><Text LanguageId="11274">Vectibix (panitumumab)</Text></Answer><Answer ObjectId="(0:0-230054210#611750598, 207)" Precode="14"><Text LanguageId="11274">Avastin (bevacizumab)</Text></Answer><Answer ObjectId="(0:0-230054211#611750603, 207)" Precode="15"><Text LanguageId="11274">Regorafenib (Stivarga)</Text></Answer><HeaderAnswer ObjectId="(0:0-230054213#611750610, 225)" Precode="h4"><Text LanguageId="11274">&lt;u&gt;Malignant Melanoma&lt;/u&gt;</Text></HeaderAnswer><Answer ObjectId="(0:0-230054214#611750612, 207)" Precode="16"><Text LanguageId="11274">Zelboraf (vemurafenib)</Text></Answer><Answer ObjectId="(0:0-230054215#611750617, 207)" Precode="17"><Text LanguageId="11274">Yervoy (ipilimumab)</Text></Answer></Answers><Scales><Scale ObjectId="(0:0-230054255#611750718, 207)" Precode="1"><Text LanguageId="11274">Inpatient</Text></Scale><Scale ObjectId="(0:0-230054256#611750722, 207)" Precode="2"><Text LanguageId="11274">Outpatient/ ambulatory</Text></Scale><Scale ObjectId="(0:0-230054257#611750726, 207)" Precode="3"><Text LanguageId="11274">Both inpatient and outpatient</Text></Scale><Scale ObjectId="(0:0-230054258#611750730, 207)" Precode="4"><Text LanguageId="11274">Not sure/Do not know</Text></Scale><Scale ObjectId="(0:0-230054259#611750734, 207)" Precode="5"><Text LanguageId="11274">Not covered</Text></Scale></Scales></Grid><Page ObjectId="(0:0-230054280#611736264, 182)" Name="Copy of Page50"><Nodes><Grid3D ObjectId="(0:0-230054282#611736270, 204)" Name="q6BM"><Title LanguageId="11274">q6BM</Title><Text LanguageId="11274">How do Seguro Popular (SP) affiliated adult patients currently access treatment for NSCLC, CRC, and Malignant Melanoma, as only CaB is included in the oncological malignancies covered by the Fondo de Protecci&#243;n contra Gastos Catastr&#243;ficos (FPcGC)?</Text><Instruction LanguageId="11274">Select all that apply per column.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230054342#611736456, 225)" Precode="h1"><Text LanguageId="11274">Patients…</Text></HeaderAnswer><Answer ObjectId="(0:0-230054343#611736458, 207)" Precode="1"><Text LanguageId="11274">must pay for treatment out of pocket</Text></Answer><Answer ObjectId="(0:0-230054344#611736463, 207)" Precode="2"><Text LanguageId="11274">receive only palliative care</Text></Answer><Answer ObjectId="(0:0-230054345#611736468, 207)" Precode="3"><Text LanguageId="11274">can get selected targeted agents via state coverage</Text></Answer><Answer ObjectId="(0:0-230054346#611736473, 207)" Precode="4"><Text LanguageId="11274">may rely on another government-sponsored medical program that covers their treatment cost</Text></Answer><Answer ObjectId="(0:0-230054347#611736478, 207)" Precode="5"><Text LanguageId="11274">may rely on a manufacturer-sponsored medical program that covers their treatment cost</Text></Answer><Answer ObjectId="(0:0-230054348#611736483, 207)" Precode="6"><Text LanguageId="11274">I don't treat SP patients</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230054284#611736277, 164)" Name="q6aBM"><Title LanguageId="11274">q6aBM</Title><Text LanguageId="11274">NSCLC</Text></Multi><Multi ObjectId="(0:0-230054300#611736325, 164)" Name="q6bBM"><Title LanguageId="11274">q6bBM</Title><Text LanguageId="11274">CRC</Text></Multi><Multi ObjectId="(0:0-230054316#611736371, 164)" Name="q6cBM"><Title LanguageId="11274">q6cBM</Title><Text LanguageId="11274">Malignant Melanoma</Text></Multi></Nodes></Grid3D><Open ObjectId="(0:0-230054368#609531314, 164)" Name="q6aBM_Other1"><Title LanguageId="11274">q6aBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via state coverage for NSCLC.</Text></Open><Open ObjectId="(0:0-230054380#609531345, 164)" Name="q6aBM_Other2"><Title LanguageId="11274">q6aBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for NSCLC.</Text></Open><Open ObjectId="(0:0-230054392#609531376, 164)" Name="q6aBM_Other3"><Title LanguageId="11274">q6aBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for NSCLC.</Text></Open><Open ObjectId="(0:0-230054404#609531407, 164)" Name="q6bBM_Other1"><Title LanguageId="11274">q6bBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via state coverage for CRC.</Text></Open><Open ObjectId="(0:0-230054416#609531438, 164)" Name="q6bBM_Other2"><Title LanguageId="11274">q6bBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for CRC.</Text></Open><Open ObjectId="(0:0-230054428#609531469, 164)" Name="q6bBM_Other3"><Title LanguageId="11274">q6bBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for CRC.</Text></Open><Open ObjectId="(0:0-230054440#609531500, 164)" Name="q6cBM_Other1"><Title LanguageId="11274">q6cBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via state coverage for Malignant Melanoma.</Text></Open><Open ObjectId="(0:0-230054452#609531532, 164)" Name="q6cBM_Other2"><Title LanguageId="11274">q6cBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for Malignant Melanoma.</Text></Open><Open ObjectId="(0:0-230054464#610472546, 164)" Name="q6cBM_Other3"><Title LanguageId="11274">q6cBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for Malignant Melanoma.</Text></Open></Nodes></Page><Page ObjectId="(0:0-230054481#610472587, 182)" Name="Copy of Copy of Page50"><Nodes><Grid3D ObjectId="(0:0-230054483#610472592, 204)" Name="q7BM"><Title LanguageId="11274">q7BM</Title><Text LanguageId="11274">How do public patients currently access treatment with targeted therapies not listed in the Sistema Unico de Reintegro (SUR) (e.g., pertuzumab [Perjeta] and ado- trastuzumab emtansine [Kadcyla] for CaB; crizotinib [Xalkori] and afatinib [Gilotrif] for NSCLC; panitumumab [Vectibix] for CRC; and vemurafenib [Zelboraf] for Malignant Melanoma)?</Text><Instruction LanguageId="11274">Select all that apply per column.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230054559#601637845, 225)" Precode="h1"><Text LanguageId="11274">Patients…</Text></HeaderAnswer><Answer ObjectId="(0:0-230054560#601637847, 207)" Precode="1"><Text LanguageId="11274">must pay for treatment out of pocket</Text></Answer><Answer ObjectId="(0:0-230054561#601637852, 207)" Precode="2"><Text LanguageId="11274">receive only palliative care</Text></Answer><Answer ObjectId="(0:0-230054562#601637857, 207)" Precode="3"><Text LanguageId="11274">can get selected targeted agents via provincial coverage</Text></Answer><Answer ObjectId="(0:0-230054563#601637862, 207)" Precode="4"><Text LanguageId="11274">may rely on another government-sponsored medical program that covers their treatment cost</Text></Answer><Answer ObjectId="(0:0-230054564#601637867, 207)" Precode="5"><Text LanguageId="11274">may rely on a manufacturer-sponsored medical program that covers their treatment cost</Text></Answer><Answer ObjectId="(0:0-230054565#601637872, 207)" Precode="6"><Text LanguageId="11274">may pursue a judicial action to get the drug (Recurso de Amparo)</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230054485#610472597, 164)" Name="q7aBM"><Title LanguageId="11274">q7aBM</Title><Text LanguageId="11274">Cab (pertuzumab; ado-trastuzumab emtansine)</Text></Multi><Multi ObjectId="(0:0-230054501#610472644, 164)" Name="q7bBM"><Title LanguageId="11274">q7bBM</Title><Text LanguageId="11274">NSCLC (crizotinib; afatinib)</Text></Multi><Multi ObjectId="(0:0-230054517#610472691, 164)" Name="q7cBM"><Title LanguageId="11274">q7cBM</Title><Text LanguageId="11274">CRC (panitumumab)</Text></Multi><Multi ObjectId="(0:0-230054533#610472737, 164)" Name="q7dBM"><Title LanguageId="11274">q7dBM</Title><Text LanguageId="11274">Malignant Melanoma (vemurafenib)</Text></Multi></Nodes></Grid3D><Open ObjectId="(0:0-230054585#601637926, 164)" Name="q7aBM_Other1"><Title LanguageId="11274">q7aBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via provincial coverage for Cab (pertuzumab; ado-trastuzumab emtansine).</Text></Open><Open ObjectId="(0:0-230054597#601637959, 164)" Name="q7aBM_Other2"><Title LanguageId="11274">q7aBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for Cab (pertuzumab; ado-trastuzumab emtansine).</Text></Open><Open ObjectId="(0:0-230054609#601637991, 164)" Name="q7aBM_Other3"><Title LanguageId="11274">q7aBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for Cab (pertuzumab; ado-trastuzumab emtansine).</Text></Open><Open ObjectId="(0:0-230054621#601638023, 164)" Name="q7bBM_Other1"><Title LanguageId="11274">q7bBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via provincial coverage for NSCLC (crizotinib; afatinib).</Text></Open><Open ObjectId="(0:0-230054633#601638055, 164)" Name="q7bBM_Other2"><Title LanguageId="11274">q7bBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for NSCLC (crizotinib; afatinib).</Text></Open><Open ObjectId="(0:0-230054645#611621941, 164)" Name="q7bBM_Other3"><Title LanguageId="11274">q7bBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for NSCLC (crizotinib; afatinib).</Text></Open><Open ObjectId="(0:0-230054657#611621973, 164)" Name="q7cBM_Other1"><Title LanguageId="11274">q7cBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via provincial coverage for CRC (panitumumab).</Text></Open><Open ObjectId="(0:0-230054669#611622005, 164)" Name="q7cBM_Other2"><Title LanguageId="11274">q7cBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for CRC (panitumumab).</Text></Open><Open ObjectId="(0:0-230054681#611622037, 164)" Name="q7cBM_Other3"><Title LanguageId="11274">q7cBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for CRC (panitumumab).</Text></Open><Open ObjectId="(0:0-230054693#611622069, 164)" Name="q7dBM_Other1"><Title LanguageId="11274">q7dBM_Other1</Title><Text LanguageId="11274">Please specify the drugs that patients can get selected targeted agents via provincial coverage for Malignant Melanoma (vemurafenib).</Text></Open><Open ObjectId="(0:0-230054705#611622101, 164)" Name="q7dBM_Other2"><Title LanguageId="11274">q7dBM_Other2</Title><Text LanguageId="11274">Please specify the the name of the government-sponsored medical program and drugs covered for Malignant Melanoma (vemurafenib).</Text></Open><Open ObjectId="(0:0-230054717#611622133, 164)" Name="q7dBM_Other3"><Title LanguageId="11274">q7dBM_Other3</Title><Text LanguageId="11274">Please specify the the name of the manufacturer-sponsored medical program and drugs covered for Malignant Melanoma (vemurafenib).</Text></Open></Nodes></Page><Page ObjectId="(0:0-230054734#611744723, 182)" Name="Page51"><Nodes><Grid3D ObjectId="(0:0-230054736#611744729, 204)" Name="q8BM"><Title LanguageId="11274">q8BM</Title><Text LanguageId="11274">Of all your Cab, NSCLC, CRC, and Malignant Melanoma patients who undergo the following mutational tests, how is the test typically paid for?</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230054828#611744940, 225)" Precode="h1"><Text LanguageId="11274">Test is paid by…</Text></HeaderAnswer><Answer ObjectId="(0:0-230054829#611744942, 207)" Precode="1"><Text LanguageId="11274">the government/social security</Text></Answer><Answer ObjectId="(0:0-230054830#611744947, 207)" Precode="2"><Text LanguageId="11274">the private health insurance</Text></Answer><Answer ObjectId="(0:0-230054831#611744952, 207)" Precode="3"><Text LanguageId="11274">the patient directly</Text></Answer><Answer ObjectId="(0:0-230054832#611744957, 207)" Precode="4"><Text LanguageId="11274">the marketing/parent company of the test</Text></Answer><Answer ObjectId="(0:0-230054833#611744962, 207)" Precode="5"><Text LanguageId="11274">contributions from both the government/social security and marketing/parent company</Text></Answer><Answer ObjectId="(0:0-230054834#611744967, 207)" Precode="6"><Text LanguageId="11274">the clinic/hospital</Text></Answer><Answer ObjectId="(0:0-230054835#611744972, 207)" Precode="98"><Text LanguageId="11274">Other</Text></Answer><Answer ObjectId="(0:0-230054836#611744977, 207)" Precode="99"><Text LanguageId="11274">None of my patients with this condition is tested for this mutation</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230054738#611744737, 164)" Name="q8aBM"><Title LanguageId="11274">q8aBM</Title><Text LanguageId="11274">Cab HER2</Text></Single><Single ObjectId="(0:0-230054754#611744772, 164)" Name="q8bBM"><Title LanguageId="11274">q8bBM</Title><Text LanguageId="11274">NSCLC EGFR</Text></Single><Single ObjectId="(0:0-230054770#611744807, 164)" Name="q8cBM"><Title LanguageId="11274">q8cBM</Title><Text LanguageId="11274">NSCLC ALK</Text></Single><Single ObjectId="(0:0-230054786#611744842, 164)" Name="q8dBM"><Title LanguageId="11274">q8dBM</Title><Text LanguageId="11274">CRC KRAS</Text></Single><Single ObjectId="(0:0-230054802#611744877, 164)" Name="q8eBM"><Title LanguageId="11274">q8eBM</Title><Text LanguageId="11274">Malignant Melanoma BRAF</Text></Single></Nodes></Grid3D><Open ObjectId="(0:0-230054859#602251036, 164)" Name="q8aBM_Other"><Title LanguageId="11274">q8aBM_Other</Title><Text LanguageId="11274">Please specify the Other for Cab HER2.</Text></Open><Open ObjectId="(0:0-230054871#602251065, 164)" Name="q8bBM_Other"><Title LanguageId="11274">q8bBM_Other</Title><Text LanguageId="11274">Please specify the Other for NSCLC EGFR.</Text></Open><Open ObjectId="(0:0-230054883#602251094, 164)" Name="q8cBM_Other"><Title LanguageId="11274">q8cBM_Other</Title><Text LanguageId="11274">Please specify the Other for NSCLC ALK.</Text></Open><Open ObjectId="(0:0-230054895#602251123, 164)" Name="q8dBM_Other"><Title LanguageId="11274">q8dBM_Other</Title><Text LanguageId="11274">Please specify the Other for CRC KRAS.</Text></Open><Open ObjectId="(0:0-230054907#602251152, 164)" Name="q8eBM_Other"><Title LanguageId="11274">q8eBM_Other</Title><Text LanguageId="11274">Please specify the Other for Malignant Melanoma BRAF.</Text></Open></Nodes></Page><Grid3D ObjectId="(0:0-230054924#602251191, 204)" Name="q9BM"><Title LanguageId="11274">q9BM</Title><Text LanguageId="11274">What percentage of your CaB patients run a diagnostic laboratory test to establish HER2 status (e.g., immunohistochemistry, fluorescence in situ hybridization, chromomeric in situ hybridization), considering the stage of the tumor at diagnosis?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230054968#611704721, 207)" Precode="1"><Text LanguageId="11274">I-II</Text></Answer><Answer ObjectId="(0:0-230054969#611704726, 207)" Precode="2"><Text LanguageId="11274">III</Text></Answer><Answer ObjectId="(0:0-230054970#611704731, 207)" Precode="3"><Text LanguageId="11274">IV</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230054926#602251196, 164)" Name="q9aBM"><Title LanguageId="11274">q9aBM</Title><Text LanguageId="11274">% of public patients</Text></Multi><Multi ObjectId="(0:0-230054942#602251237, 164)" Name="q9bBM"><Title LanguageId="11274">q9bBM</Title><Text LanguageId="11274">% of private patients</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230054986#611704766, 204)" Name="q10aBM"><Title LanguageId="11274">q10aBM</Title><Text LanguageId="11274">When do you typically test your CaB patients for HER2 status?</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230055030#611704873, 207)" Precode="1"><Text LanguageId="11274">Immediately upon diagnosis (independent of the stage)</Text></Answer><Answer ObjectId="(0:0-230055031#611704878, 207)" Precode="2"><Text LanguageId="11274">After relapse of adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055032#611704883, 207)" Precode="3"><Text LanguageId="11274">After tumor removal surgery</Text></Answer><Answer ObjectId="(0:0-230055033#611704888, 207)" Precode="4"><Text LanguageId="11274">Before initiation of first-line metastatic/advanced treatment (upon diagnosis only if stages III/IV)</Text></Answer><Answer ObjectId="(0:0-230055034#611704893, 207)" Precode="5"><Text LanguageId="11274">After initiation of first-line metastatic/advanced treatment but before second-line treatment</Text></Answer><Answer ObjectId="(0:0-230055035#611704898, 207)" Precode="6"><Text LanguageId="11274">After initiation of second-line metastatic/advanced treatment but before third-line treatment</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230054988#611704773, 164)" Name="q10aBM_a"><Title LanguageId="11274">q10aBM_a</Title><Text LanguageId="11274">Public patients</Text></Single><Single ObjectId="(0:0-230055004#611704811, 164)" Name="q10aBM_b"><Title LanguageId="11274">q10aBM_b</Title><Text LanguageId="11274">Private patients</Text></Single></Nodes></Grid3D><Page ObjectId="(0:0-230055053#601857049, 182)" Name="Page52"><Nodes><Info ObjectId="(0:0-230055055#601857055, 164)" Name="q10bBM"><Title LanguageId="11274">q10bBM</Title><Text LanguageId="11274">For what percentage of all your CaB patients whose tumor tissue is currently sent for molecular testing do you receive a conclusive test result?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction></Info><Open ObjectId="(0:0-230055066#601857084, 164)" Name="q10bBM_a"><Title LanguageId="11274">q10bBM_a</Title><Text LanguageId="11274">Public patients</Text></Open><Open ObjectId="(0:0-230055078#601857118, 164)" Name="q10bBM_b"><Title LanguageId="11274">q10bBM_b</Title><Text LanguageId="11274">Private patients</Text></Open></Nodes></Page><Page ObjectId="(0:0-230055095#601857164, 182)" Name="Copy of Page52"><Nodes><Info ObjectId="(0:0-230055097#601857170, 164)" Name="q10cBM"><Title LanguageId="11274">q10cBM</Title><Text LanguageId="11274">How long does it usually take before you receive the test results?</Text><Instruction LanguageId="11274">Enter a whole number of days.</Instruction></Info><Open ObjectId="(0:0-230055108#601857196, 164)" Name="q10cBM_a"><Title LanguageId="11274">q10cBM_a</Title><Text LanguageId="11274">Public patients</Text></Open><Open ObjectId="(0:0-230055120#601857228, 164)" Name="q10cBM_b"><Title LanguageId="11274">q10cBM_b</Title><Text LanguageId="11274">Private patients</Text></Open></Nodes></Page><Page ObjectId="(0:0-230055137#601857269, 182)" Name="Page63"><Nodes><Multi ObjectId="(0:0-230055139#601857275, 164)" Name="q11aBM"><Title LanguageId="11274">q11aBM</Title><Text LanguageId="11274">What most restricts your testing for HER2 in your newly diagnosed CaB patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason OR select &quot;Nothing restricts testing, it is entirely my decision.&quot;</Instruction><Answers><Answer ObjectId="(0:0-230055149#601857317, 207)" Precode="1"><Text LanguageId="11274">Lack of coverage for the test</Text></Answer><Answer ObjectId="(0:0-230055150#601857322, 207)" Precode="2"><Text LanguageId="11274">Hospital/clinic restrict patient criteria for screening</Text></Answer><Answer ObjectId="(0:0-230055151#601857327, 207)" Precode="3"><Text LanguageId="11274">Patient out of pocket costs</Text></Answer><Answer ObjectId="(0:0-230055152#601857332, 207)" Precode="4"><Text LanguageId="11274">Access to testing facilities</Text></Answer><Answer ObjectId="(0:0-230055153#601857337, 207)" Precode="5"><Text LanguageId="11274">Need to treat before test results are available</Text></Answer><Answer ObjectId="(0:0-230055154#601857342, 207)" Precode="6"><Text LanguageId="11274">Lack of availability of tissue for testing/would require rebiopsy</Text></Answer><Answer ObjectId="(0:0-230055155#601857347, 207)" Precode="7"><Text LanguageId="11274">Restricted access to targeted drug (i.e. trastuzumab [Herceptin], pertuzumab [Perjeta], lapatinib [Takerb])</Text></Answer><Answer ObjectId="(0:0-230055156#601857352, 207)" Precode="8"><Text LanguageId="11274">Molecular results does not impact my treatment decision</Text></Answer><Answer ObjectId="(0:0-230055157#601857357, 207)" Precode="9"><Text LanguageId="11274">The mutation occurs in too few patients to justify the cost/time taken to test</Text></Answer><Answer ObjectId="(0:0-230055158#601857362, 207)" Precode="10"><Text LanguageId="11274">Patient denies being tested</Text></Answer><Answer ObjectId="(0:0-230055159#601857367, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230055188#608034756, 164)" Name="q11bBM"><Title LanguageId="11274">q11bBM</Title><Answers><Answer ObjectId="(0:0-230055198#608034781, 207)" Precode="99"><Text LanguageId="11274">Nothing restricts testing, it is entirely my decision</Text></Answer></Answers></Multi></Nodes></Page><Grid3D ObjectId="(0:0-230055212#608034814, 204)" Name="q12BM"><Title LanguageId="11274">q12BM</Title><Text LanguageId="11274">Please estimate what proportion of your early stage (stage I-III tumors) HER2+ CaB patients currently receive each indicated therapy as a neoadjuvant treatment and the proportion you expect to receive each indicated therapy, by the end of 2017.</Text><Instruction LanguageId="11274">Must sum to 100%.  Please bear in mind:
&lt;p&gt;A.	The potential approval of Perjeta + Herceptin and docetaxel for neoadjuvant, early-stage HER2+ CaB in your market (approved in this setting in September 2013 by the U.S. FDA)
&lt;p&gt;B.	The expected launch of biosimilar trastuzumab by 2016/2017
&lt;p&gt;C.	Your knowledge of the reimbursement/funding situation in your hospital, region or country</Instruction><Answers><Answer ObjectId="(0:0-230055288#611345631, 207)" Precode="1"><Text LanguageId="11274">Trastuzumab (Herceptin/biosimilar) + chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055289#611345636, 207)" Precode="2"><Text LanguageId="11274">Pertuzumab (Perjeta) + trastuzumab (Herceptin/biosimilar) + chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055290#611345641, 207)" Precode="3"><Text LanguageId="11274">Chemotherapy only</Text></Answer><Answer ObjectId="(0:0-230055291#611345646, 207)" Precode="4"><Text LanguageId="11274">No neoadjuvant therapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230055214#608034819, 164)" Name="q12aBM"><Title LanguageId="11274">q12aBM</Title><Text LanguageId="11274">% of public patients - Current</Text></Multi><Multi ObjectId="(0:0-230055230#608034868, 164)" Name="q12bBM"><Title LanguageId="11274">q12bBM</Title><Text LanguageId="11274">% of public patients - 2017</Text></Multi><Multi ObjectId="(0:0-230055246#608034910, 164)" Name="q12cBM"><Title LanguageId="11274">q12cBM</Title><Text LanguageId="11274">% of private patients - Current</Text></Multi><Multi ObjectId="(0:0-230055262#608034959, 164)" Name="q12dBM"><Title LanguageId="11274">q12dBM</Title><Text LanguageId="11274">% of private patients - 2017</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230055305#611345693, 204)" Name="q13BM"><Title LanguageId="11274">q13BM</Title><Text LanguageId="11274">Please estimate what proportion of your early stage (I to III), HER2+ operable CaB patients currently receive each indicated therapy as an adjuvant treatment.</Text><Instruction LanguageId="11274">Enter whole percentages. Must sum to 100%.</Instruction><Answers><Answer ObjectId="(0:0-230055349#611345811, 207)" Precode="1"><Text LanguageId="11274">Trastuzumab (Herceptin) + chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055350#611345816, 207)" Precode="2"><Text LanguageId="11274">Chemotherapy only</Text></Answer><Answer ObjectId="(0:0-230055351#611345821, 207)" Precode="3"><Text LanguageId="11274">No adjuvant therapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230055307#611345700, 164)" Name="q13aBM"><Title LanguageId="11274">q13aBM</Title><Text LanguageId="11274">% of public patients</Text></Multi><Multi ObjectId="(0:0-230055323#611345742, 164)" Name="q13bBM"><Title LanguageId="11274">q13bBM</Title><Text LanguageId="11274">% of private patients</Text></Multi></Nodes></Grid3D><Info ObjectId="(0:0-230055366#611775827, 164)" Name="Lapatinib"><Title LanguageId="11274">Lapatinib</Title><Text LanguageId="11274">&lt;P style=&quot;MARGIN: 0in 0in 0pt&quot; class=MsoNoSpacing&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;The Phase III ALTTO trial is evaluating lapatinib (&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;Tykerb&lt;/B&gt;) in the &lt;U&gt;adjuvant&lt;/U&gt; treatment setting for HER2+ CaB: &lt;/SPAN&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE style=&quot;BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; MARGIN: auto auto auto 21.05pt; WIDTH: 88.44%; BORDER-COLLAPSE: collapse; BORDER-TOP: medium none; BORDER-RIGHT: medium none; mso-border-alt: solid black .5pt; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-insideh: .5pt solid black; mso-border-insidev: .5pt solid black&quot; class=MsoNormalTable border=1 cellSpacing=0 cellPadding=0 width=&quot;88%&quot;&gt;
&lt;TBODY&gt;
&lt;TR style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 100%; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt&quot; width=&quot;100%&quot;&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Lapatinib (Tykerb)&amp;nbsp;&lt;SPAN style=&quot;mso-spacerun: yes&quot;&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;HEIGHT: 3.5pt; mso-yfti-irow: 1; mso-yfti-lastrow: yes&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 100%; PADDING-RIGHT: 5.4pt; HEIGHT: 3.5pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=&quot;100%&quot;&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;U&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Phase III ALLTO trial&lt;U&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/U&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;U&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Treatment Arms:&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;1) Herceptin only&lt;SPAN style=&quot;mso-spacerun: yes&quot;&gt;&amp;nbsp; &lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Herceptin + chemotherapy (12 weeks) &lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: wingdings; FONT-SIZE: 10pt; mso-ascii-font-family: arial; mso-fareast-font-family: timesnewromanpsmt; mso-hansi-font-family: arial; mso-bidi-font-family: arial; mso-ansi-language: en-us; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;SPAN style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt; Herceptin (40 weeks)
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;2) Sequential treatment with Herceptin followed by Tykerb
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Herceptin + chemotherapy (12 or 18 weeks) &lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: wingdings; FONT-SIZE: 10pt; mso-ascii-font-family: arial; mso-fareast-font-family: timesnewromanpsmt; mso-hansi-font-family: arial; mso-bidi-font-family: arial; mso-ansi-language: en-us; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;SPAN style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt; Treatment-free interval (6 weeks) &lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: wingdings; FONT-SIZE: 10pt; mso-ascii-font-family: arial; mso-fareast-font-family: timesnewromanpsmt; mso-hansi-font-family: arial; mso-bidi-font-family: arial; mso-ansi-language: en-us; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;SPAN style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt; Tykerb (34 or 28 weeks)
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;3) Concurrent treatment with Herceptin and Tykerb 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Herceptin + Tykerb + chemotherapy (12 weeks) &lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: wingdings; FONT-SIZE: 10pt; mso-ascii-font-family: arial; mso-fareast-font-family: timesnewromanpsmt; mso-hansi-font-family: arial; mso-bidi-font-family: arial; mso-ansi-language: en-us; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;SPAN style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt; Herceptin + Tykerb (40 weeks)&lt;/SPAN&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;Primary end point: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'times new roman'; mso-ansi-language: en-us&quot;&gt;Disease-free survival&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt; (DFS)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;</Text></Info><Multi ObjectId="(0:0-230055377#611776108, 164)" Name="q14BM"><Title LanguageId="11274">q14BM</Title><Text LanguageId="11274">In comparison to Herceptin alone, what is your opinion of Tykerb + Herceptin as adjuvant treatment for HER2+ CaB?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230055387#611776147, 225)" Precode="h1"><Text LanguageId="11274">I expect this therapy…</Text></HeaderAnswer><Answer ObjectId="(0:0-230055388#611776149, 207)" Precode="1"><Text LanguageId="11274">to demonstrate superior efficacy over Herceptin alone as an adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055389#611776154, 207)" Precode="2"><Text LanguageId="11274">to gain regulatory approval as an adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055390#611776159, 207)" Precode="3"><Text LanguageId="11274">to demonstrate benefits, once Tykerb has the potential to cross the blood-brain barrier and protect against brain metastases as a small molecule</Text></Answer><Answer ObjectId="(0:0-230055391#611776164, 207)" Precode="4"><Text LanguageId="11274">not to be advantageous, once the benefits of an oral administration are negated when used concurrently with Herceptin</Text></Answer><Answer ObjectId="(0:0-230055392#611776169, 207)" Precode="5"><Text LanguageId="11274">to be included in the national coverage formularies</Text></Answer><Answer ObjectId="(0:0-230055393#611776174, 207)" Precode="6"><Text LanguageId="11274">will not be included in the national coverage formularies</Text></Answer><Answer ObjectId="(0:0-230055394#611776179, 207)" Precode="7"><Text LanguageId="11274">will not be covered in my hospital/institution as an adjuvant treatment due to cost</Text></Answer><Answer ObjectId="(0:0-230055395#611776184, 207)" Precode="8"><Text LanguageId="11274">raise some toxicity concerns as an adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055396#611776189, 207)" Precode="9"><Text LanguageId="11274">will only be used for poor prognosis patients as an adjuvant treatment</Text></Answer></Answers></Multi><Info ObjectId="(0:0-230055422#611776273, 164)" Name="Pertuzumab"><Title LanguageId="11274">Pertuzumab</Title><Text LanguageId="11274">&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt; mso-add-space: auto&quot; class=&quot;MsoListParagraph&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-fareast-language: en-gb&quot;&gt;The Phase III APHINITY trial is evaluating pertuzumab (&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;Perjeta&lt;/b&gt;) &lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;in combination with&lt;/b&gt; trastuzumab (&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;Herceptin&lt;/b&gt;) compared with Herceptin as &lt;u&gt;adjuvant&lt;/u&gt; treatments for HER2+ CaB:&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: timesnewromanpsmt; mso-ansi-language: en-us; mso-fareast-language: en-gb&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;table style=&quot;border-bottom: medium none; border-left: medium none; margin: auto auto auto 21.05pt; width: 389.8pt; border-collapse: collapse; border-top: medium none; border-right: medium none; mso-border-alt: solid black .5pt; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-insideh: .5pt solid black; mso-border-insidev: .5pt solid black&quot; class=&quot;MsoNormalTable&quot; border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;520&quot;&gt;&lt;tbody&gt;&lt;tr style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 389.8pt; padding-right: 5.4pt; background: #c6d9f1; border-top: black 1pt solid; border-right: black 1pt solid; padding-top: 0in; mso-border-alt: solid black .5pt&quot; width=&quot;520&quot;&gt;&lt;p style=&quot;margin: 0in 0in 0pt&quot; class=&quot;MsoNoSpacing&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;Pertuzumab (Perjeta) &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=&quot;height: 101.65pt; mso-yfti-irow: 1; mso-yfti-lastrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0in; background-color: transparent; padding-left: 5.4pt; width: 389.8pt; padding-right: 5.4pt; height: 101.65pt; border-top: #f0f0f0; border-right: black 1pt solid; padding-top: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=&quot;520&quot;&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Phase III APHINITY Trial: Adjuvant treatment for HER2+ CaB&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt; (non-metastatic)&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;margin: 0in 0in 0pt&quot; class=&quot;MsoNoSpacing&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;u&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;Treatment arms:&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1&quot; class=&quot;MsoListParagraphCxSpFirst&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: arial&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;1)&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;Herceptin + chemotherapy for 6-8 cycles followed by Herceptin for up to 1 year&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1&quot; class=&quot;MsoListParagraphCxSpLast&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: arial&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;2)&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;Herceptin + Perjeta + chemotherapy for 6-8 cycles followed by Herceptin + Perjeta for up to 1 year&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Primary end point:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt; Invasive DFS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</Text></Info><Multi ObjectId="(0:0-230055436#611776456, 164)" Name="q15BM"><Title LanguageId="11274">q15BM</Title><Text LanguageId="11274">In comparison to Herceptin alone, what is your opinion of Perjeta + Herceptin as adjuvant treatment for HER2+ CaB?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230055446#611776495, 225)" Precode="h1"><Text LanguageId="11274">I expect this therapy…</Text></HeaderAnswer><Answer ObjectId="(0:0-230055447#611776497, 207)" Precode="1"><Text LanguageId="11274">to demonstrate superior efficacy over Herceptin alone as an adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055448#611776502, 207)" Precode="2"><Text LanguageId="11274">to gain regulatory approval as an adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055449#611776507, 207)" Precode="3"><Text LanguageId="11274">will be best reserved for treatment of metastatic disease</Text></Answer><Answer ObjectId="(0:0-230055450#611776512, 207)" Precode="4"><Text LanguageId="11274">to be included in the national coverage formularies</Text></Answer><Answer ObjectId="(0:0-230055451#611776517, 207)" Precode="5"><Text LanguageId="11274">will not be included in the national coverage formularies</Text></Answer><Answer ObjectId="(0:0-230055452#611776522, 207)" Precode="6"><Text LanguageId="11274">will not be covered in my hospital/institution as an adjuvant treatment due to cost</Text></Answer><Answer ObjectId="(0:0-230055453#611776527, 207)" Precode="7"><Text LanguageId="11274">raise some toxicity concerns as an adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055454#611776532, 207)" Precode="8"><Text LanguageId="11274">will not be a standard therapeutic option, because I do not think it is necessary to continue treatment with an agent containing a chemotherapeutic component for the entire duration of adjuvant treatment</Text></Answer><Answer ObjectId="(0:0-230055455#611776537, 207)" Precode="9"><Text LanguageId="11274">will only be used for poor prognosis patients as an adjuvant treatment</Text></Answer></Answers></Multi><Grid3D ObjectId="(0:0-230055484#611744173, 204)" Name="q16BM"><Title LanguageId="11274">q16BM</Title><Text LanguageId="11274">Please estimate what proportion of your early stage (I to III), HER2+ operable CaB patients will be receiving each indicated therapy as an adjuvant treatment by the end of 2017.</Text><Instruction LanguageId="11274">Must sum to 100%. For your reference, the percentages you estimated for your current use of these treatments are shown below. Please bear in mind:
&lt;p&gt;A.	The expected launch of biosimilar trastuzumab
&lt;p&gt;B.	Your own clinical experience and preferences, but also your knowledge of the reimbursement/funding situation in your hospital, region or country</Instruction><Answers><Answer ObjectId="(0:0-230055560#611744376, 207)" Precode="1"><Text LanguageId="11274">Trastuzumab (Herceptin/biosimilar) + chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055561#611744381, 207)" Precode="2"><Text LanguageId="11274">Chemotherapy only</Text></Answer><Answer ObjectId="(0:0-230055562#611744386, 207)" Precode="3"><Text LanguageId="11274">Trastuzumab (Herceptin/biosimilar) + chemotherapy  + lapatinib (Tykerb) (sequential treatment)</Text></Answer><Answer ObjectId="(0:0-230055563#611744391, 207)" Precode="4"><Text LanguageId="11274">Trastuzumab (Herceptin/biosimilar) + lapatinib (Tykerb) + chemotherapy  + Herceptin + Tykerb (concurrent treatment)</Text></Answer><Answer ObjectId="(0:0-230055564#611744396, 207)" Precode="5"><Text LanguageId="11274">Pertuzumab (Perjeta) + trastuzumab (Herceptin/biosimilar) + chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055565#611744401, 207)" Precode="6"><Text LanguageId="11274">No adjuvant chemotherapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230055486#611744180, 164)" Name="q16aBM"><Title LanguageId="11274">q16aBM</Title><Text LanguageId="11274">% of public patients - Current</Text></Multi><Multi ObjectId="(0:0-230055502#611744222, 164)" Name="q16bBM"><Title LanguageId="11274">q16bBM</Title><Text LanguageId="11274">% of public patients - 2017</Text></Multi><Multi ObjectId="(0:0-230055518#611744264, 164)" Name="q16cBM"><Title LanguageId="11274">q16cBM</Title><Text LanguageId="11274">% of private patients - Current</Text></Multi><Multi ObjectId="(0:0-230055534#611744306, 164)" Name="q16dBM"><Title LanguageId="11274">q16dBM</Title><Text LanguageId="11274">% of private patients - 2017</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230055586#611462535, 204)" Name="q17BM"><Title LanguageId="11274">q17BM</Title><Text LanguageId="11274">What percentage of your HER2+ (irrespective of HR status) CaB public patients with advanced/metastatic disease receives the following targeted agents (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q17aBM_99&quot;) != null)
document.getElementById(&quot;q17aBM_99&quot;).disabled = true;
document.getElementById(&quot;q17aBM_99&quot;).style.backgroundColor = &quot;#EAEAEA&quot;;
}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Enter whole percentages. Must sum to 100% for each column.</Instruction><Answers><Answer ObjectId="(0:0-230055646#611462758, 207)" Precode="1"><Text LanguageId="11274">Ado-trastuzumab emtansine (Kadcyla)</Text></Answer><Answer ObjectId="(0:0-230055647#611462763, 207)" Precode="2"><Text LanguageId="11274">Trastuzumab (Herceptin)</Text></Answer><Answer ObjectId="(0:0-230055648#611462768, 207)" Precode="3"><Text LanguageId="11274">Trastuzumab (Herceptin) + pertuzumab (Perjeta)</Text></Answer><Answer ObjectId="(0:0-230055649#611462773, 207)" Precode="4"><Text LanguageId="11274">Trastuzumab (Herceptin) + lapatinib (Tykerb) (off-label)</Text></Answer><Answer ObjectId="(0:0-230055650#611462778, 207)" Precode="5"><Text LanguageId="11274">Lapatinib (Tykerb)</Text></Answer><Answer ObjectId="(0:0-230055651#611462783, 207)" Precode="6"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230055652#611462788, 207)" Precode="7"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230055653#611462793, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230055588#611462542, 164)" Name="q17aBM"><Title LanguageId="11274">q17aBM</Title><Text LanguageId="11274">First-line</Text></Multi><Multi ObjectId="(0:0-230055604#611462596, 164)" Name="q17bBM"><Title LanguageId="11274">q17bBM</Title><Text LanguageId="11274">Second-line</Text></Multi><Multi ObjectId="(0:0-230055620#611462659, 164)" Name="q17cBM"><Title LanguageId="11274">q17cBM</Title><Text LanguageId="11274">Third-line</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230055678#578247512, 204)" Name="q18BM"><Title LanguageId="11274">q18BM</Title><Text LanguageId="11274">What percentage of your HER2+ (irrespective of HR status) CaB private patients with advanced/metastatic disease receives the following targeted agents (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q18aBM_99&quot;) != null)
document.getElementById(&quot;q18aBM_99&quot;).disabled = true;
document.getElementById(&quot;q18aBM_99&quot;).style.backgroundColor = &quot;#EAEAEA&quot;;
}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Enter whole percentages. Must sum to 100% for each column.</Instruction><Answers><Answer ObjectId="(0:0-230055738#578247735, 207)" Precode="1"><Text LanguageId="11274">Ado-trastuzumab emtansine (Kadcyla)</Text></Answer><Answer ObjectId="(0:0-230055739#578247740, 207)" Precode="2"><Text LanguageId="11274">Trastuzumab (Herceptin)</Text></Answer><Answer ObjectId="(0:0-230055740#578247745, 207)" Precode="3"><Text LanguageId="11274">Trastuzumab (Herceptin) + pertuzumab (Perjeta)</Text></Answer><Answer ObjectId="(0:0-230055741#578247750, 207)" Precode="4"><Text LanguageId="11274">Trastuzumab (Herceptin) + lapatinib (Tykerb) (off-label)</Text></Answer><Answer ObjectId="(0:0-230055742#578247755, 207)" Precode="5"><Text LanguageId="11274">Lapatinib (Tykerb)</Text></Answer><Answer ObjectId="(0:0-230055743#578247760, 207)" Precode="6"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230055744#578247765, 207)" Precode="7"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230055745#578247770, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230055680#578247519, 164)" Name="q18aBM"><Title LanguageId="11274">q18aBM</Title><Text LanguageId="11274">First-line</Text></Multi><Multi ObjectId="(0:0-230055696#578247573, 164)" Name="q18bBM"><Title LanguageId="11274">q18bBM</Title><Text LanguageId="11274">Second-line</Text></Multi><Multi ObjectId="(0:0-230055712#578247636, 164)" Name="q18cBM"><Title LanguageId="11274">q18cBM</Title><Text LanguageId="11274">Third-line</Text></Multi></Nodes></Grid3D><Multi ObjectId="(0:0-230055770#578252666, 164)" Name="q20BM"><Title LanguageId="11274">q20BM</Title><Text LanguageId="11274">Which of the following statements do you agree with when considering Kadcyla + Perjeta combination treatment as first-line therapy for HER2+ advanced/metastatic CaB?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230055780#578252693, 225)" Precode="h1"><Text LanguageId="11274">Kadcyla + Perjeta combination will likely…</Text></HeaderAnswer><Answer ObjectId="(0:0-230055781#578252695, 207)" Precode="1"><Text LanguageId="11274">demonstrate a significant efficacy benefit over Herceptin plus chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055782#578252700, 207)" Precode="2"><Text LanguageId="11274">demonstrate a significant efficacy benefit over Kadcyla alone</Text></Answer><Answer ObjectId="(0:0-230055783#578252705, 207)" Precode="3"><Text LanguageId="11274">face a favorable environment for inclusion in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230055784#578252710, 207)" Precode="4"><Text LanguageId="11274">face a favorable environment for inclusion in the private sector hospital/institutional formularies</Text></Answer><Answer ObjectId="(0:0-230055785#578252715, 207)" Precode="99"><Text LanguageId="11274">I do not predict to prescribe this treatment</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230055810#578252791, 164)" Name="q21BM"><Title LanguageId="11274">q21BM</Title><Text LanguageId="11274">Which of the following statements do you agree with when NOT considering Kadcyla + Perjeta combination treatment as first-line therapy for HER2+ advanced/metastatic CaB?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason, etc.</Instruction><Answers><HeaderAnswer ObjectId="(0:0-230055820#578252831, 225)" Precode="h1"><Text LanguageId="11274">Kadcyla + Perjeta combination will not likely…</Text></HeaderAnswer><Answer ObjectId="(0:0-230055821#578252833, 207)" Precode="1"><Text LanguageId="11274">demonstrate any benefit over Herceptin plus chemotherapy</Text></Answer><Answer ObjectId="(0:0-230055822#578252838, 207)" Precode="2"><Text LanguageId="11274">demonstrate any efficacy benefit over Kadcyla alone</Text></Answer><Answer ObjectId="(0:0-230055823#578252843, 207)" Precode="3"><Text LanguageId="11274">be prescribed due to the increased infusion time</Text></Answer><Answer ObjectId="(0:0-230055824#578252848, 207)" Precode="4"><Text LanguageId="11274">be prescribed due to the overall cost of this combination</Text></Answer><Answer ObjectId="(0:0-230055825#578252853, 207)" Precode="5"><Text LanguageId="11274">be included in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230055826#578252858, 207)" Precode="6"><Text LanguageId="11274">be included in the private sector hospital/institutional formularies</Text></Answer><Answer ObjectId="(0:0-230055827#578252863, 207)" Precode="7"><Text LanguageId="11274">be covered in my hospital/institution</Text></Answer></Answers></Multi><Grid3D ObjectId="(0:0-230055850#578252932, 204)" Name="q22BM"><Title LanguageId="11274">q22BM</Title><Text LanguageId="11274">If all of the following treatments were approved by the regulatory agencies in your country and 100% funded/covered/ reimbursed for advanced/metastatic HER2+ CaB by the patient’s health insurance plan and/or by the government or ^f('Sq1').get() == '1' ? &quot;Social Security&quot; : &quot;the Obras Sociales&quot;^, which one would you primarily consider prescribing to your patients (+/- chemotherapy)?


&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q22aBM_7&quot;) != null)
document.getElementById(&quot;q22aBM_7&quot;).disabled = true;

if(document.getElementById(&quot;q22aBM_99&quot;) != null)
document.getElementById(&quot;q22aBM_99&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230055910#602021153, 207)" Precode="1"><Text LanguageId="11274">Ado-trastuzumab emtansine (Kadcyla)</Text></Answer><Answer ObjectId="(0:0-230055911#602021158, 207)" Precode="2"><Text LanguageId="11274">Trastuzumab (Herceptin)</Text></Answer><Answer ObjectId="(0:0-230055912#602021163, 207)" Precode="3"><Text LanguageId="11274">Trastuzumab (Herceptin) + pertuzumab (Perjeta)</Text></Answer><Answer ObjectId="(0:0-230055913#602021168, 207)" Precode="4"><Text LanguageId="11274">Lapatinib (Tykerb)</Text></Answer><Answer ObjectId="(0:0-230055914#602021173, 207)" Precode="5"><Text LanguageId="11274">Trastuzumab (Herceptin) + lapatinib (Tykerb)</Text></Answer><Answer ObjectId="(0:0-230055915#602021178, 207)" Precode="6"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230055916#602021183, 207)" Precode="7"><Text LanguageId="11274">Ado-trastuzumab emtansine (Kadcyla) + pertuzumab (Perjeta)</Text></Answer><Answer ObjectId="(0:0-230055917#602021188, 207)" Precode="8"><Text LanguageId="11274">No targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230055918#602021193, 207)" Precode="99"><Text LanguageId="11274">I would not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230055852#578252937, 164)" Name="q22aBM"><Title LanguageId="11274">q22aBM</Title><Text LanguageId="11274">First-line</Text></Single><Single ObjectId="(0:0-230055868#602021039, 164)" Name="q22bBM"><Title LanguageId="11274">q22bBM</Title><Text LanguageId="11274">Second-line</Text></Single><Single ObjectId="(0:0-230055884#602021074, 164)" Name="q22cBM"><Title LanguageId="11274">q22cBM</Title><Text LanguageId="11274">Third-line</Text></Single></Nodes></Grid3D><Grid3D ObjectId="(0:0-230055942#602021255, 204)" Name="q23BM"><Title LanguageId="11274">q23BM</Title><Text LanguageId="11274">Among all your HER2+ CaB patients receiving a neoadjuvant, adjuvant or metastatic/advanced treatment with trastuzumab by the end of 2017, and assuming the launch of biosimilar trastuzumab in your country, what proportion do you estimate will receive the branded version of trastuzumab (Herceptin) and the biosimilar trastuzumab?</Text><Instruction LanguageId="11274">Must sum to 100%.</Instruction><Answers><Answer ObjectId="(0:0-230055986#611776693, 207)" Precode="1"><Text LanguageId="11274">Herceptin</Text></Answer><Answer ObjectId="(0:0-230055987#611776698, 207)" Precode="2"><Text LanguageId="11274">Biosimilar trastuzumab</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230055944#602021260, 164)" Name="q23aBM"><Title LanguageId="11274">q23aBM</Title><Text LanguageId="11274">% of public patients</Text></Multi><Multi ObjectId="(0:0-230055960#611776620, 164)" Name="q23bBM"><Title LanguageId="11274">q23bBM</Title><Text LanguageId="11274">% of private patients</Text></Multi></Nodes></Grid3D><Info ObjectId="(0:0-230055997#611776721, 164)" Name="BMN673Niraparib"><Title LanguageId="11274">BMN673Niraparib</Title><Text LanguageId="11274">&lt;P style=&quot;MARGIN: 0in 0in 8pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Inhibition of Poly ADP-Ribose Polymerase (&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;PARP&lt;/B&gt;) has emerged as a therapeutic strategy in DNA-repair-deficient tumors, such as BRCA1/2-mutated tumors. Please review the clinical profiles for &lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;BMN-673&lt;/B&gt; and &lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;niraparib&lt;/B&gt;:&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE style=&quot;BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; MARGIN: auto auto auto 13.95pt; WIDTH: 382.7pt; BORDER-COLLAPSE: collapse; BORDER-TOP: medium none; BORDER-RIGHT: medium none; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-alt: solid black .5pt; mso-border-insideh: .5pt solid black; mso-border-insidev: .5pt solid black&quot; class=MsoNormalTable border=1 cellSpacing=0 cellPadding=0 width=510&gt;
&lt;TBODY&gt;
&lt;TR style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.5pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;
&lt;P&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 141.75pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt&quot; width=189&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;BMN-673&lt;SPAN style=&quot;mso-spacerun: yes&quot;&gt;&amp;nbsp; &lt;/SPAN&gt;(BioMarin)&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.45pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Niraparib&lt;SPAN style=&quot;mso-spacerun: yes&quot;&gt;&amp;nbsp; &lt;/SPAN&gt;(Tesaro)&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;HEIGHT: 11.1pt; mso-yfti-irow: 1&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.5pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; HEIGHT: 11.1pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: calibri&quot;&gt;Dosing&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 141.75pt; PADDING-RIGHT: 5.4pt; HEIGHT: 11.1pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=189&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;1.0&lt;B&gt; &lt;/B&gt;mg (oral) once daily&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 120.45pt; PADDING-RIGHT: 5.4pt; HEIGHT: 11.1pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;100 mg (oral) once daily&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;mso-yfti-irow: 2&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.5pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: calibri&quot;&gt;Development status&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 141.75pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=189&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Phase III (no ongoing or completed trials in Mexico and Argentina)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 120.45pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Phase III (1 ongoing trial in Mexico; no ongoing or completed trials in Argentina)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;mso-yfti-irow: 3&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.5pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Phase I data&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 141.75pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=189&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo2&quot; class=MsoListParagraphCxSpFirst&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol; mso-fareast-language: en-gb&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Complete response (CR) or Partial response (PR): 44%&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'times new roman'; mso-fareast-language: en-gb&quot;&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo2&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol; mso-fareast-language: en-gb&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Clinical benefit rate (CBR): 72%&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'times new roman'; mso-fareast-language: en-gb&quot;&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo2&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol; mso-fareast-language: en-gb&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Median duration of response: 27.9 weeks&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'times new roman'; mso-fareast-language: en-gb&quot;&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo2&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol; mso-fareast-language: en-gb&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Progression-free survival (PFS): 33.1 weeks&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 120.45pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo1&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol; mso-fareast-language: en-gb&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;MTD: 300mg once daily&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'times new roman'; mso-fareast-language: en-gb&quot;&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo1&quot; class=MsoListParagraphCxSpLast&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol; mso-fareast-language: en-gb&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Of four CaB patients in the trial with &lt;I&gt;BRCA1/2&lt;/I&gt; mutations, two experienced a partial response to treatment&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;HEIGHT: 34.95pt; mso-yfti-irow: 4&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.5pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; HEIGHT: 34.95pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Most common grade 3/4 adverse events&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 141.75pt; PADDING-RIGHT: 5.4pt; HEIGHT: 34.95pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=189&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Thrombocytopenia (17.5%), anemia (15%) and neutropenia (6.3%)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 120.45pt; PADDING-RIGHT: 5.4pt; HEIGHT: 34.95pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri; mso-fareast-language: en-gb; mso-font-kerning: 12.0pt&quot;&gt;Thrombocytopenia (15%), anemia (10%), neutropenia (4%), and fatigue (4%)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;HEIGHT: 8.95pt; mso-yfti-irow: 5; mso-yfti-lastrow: yes&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 120.5pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; HEIGHT: 8.95pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: calibri&quot;&gt;Expected launch date&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 141.75pt; PADDING-RIGHT: 5.4pt; HEIGHT: 8.95pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=189&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: calibri&quot;&gt;2017&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 120.45pt; PADDING-RIGHT: 5.4pt; HEIGHT: 8.95pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=161&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: calibri&quot;&gt;2016&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;</Text></Info><Grid3D ObjectId="(0:0-230056008#611777291, 204)" Name="q24BM"><Title LanguageId="11274">q24BM</Title><Text LanguageId="11274">Assuming that BMN-673 and niraparib are approved by the regulatory agencies in your country for germline BRCA mutation-positive advanced/metastatic CaB patients, how important will approval of a companion biomarker test be in your decision to prescribe these agents?</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230056052#611777399, 207)" Precode="1"><Text LanguageId="11274">I will only prescribe if a validated companion biomarker test is available</Text></Answer><Answer ObjectId="(0:0-230056053#611777404, 207)" Precode="2"><Text LanguageId="11274">I am unlikely to prescribe unless a validated companion biomarker test is available</Text></Answer><Answer ObjectId="(0:0-230056054#611777409, 207)" Precode="3"><Text LanguageId="11274">I would not be deterred from prescribing if approved without a companion biomarker test</Text></Answer><Answer ObjectId="(0:0-230056055#611777414, 207)" Precode="4"><Text LanguageId="11274">I am unconvinced by the benefit of this agent, regardless of the availability of a companion biomarker test, and I would not prescribe it</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230056010#611777299, 164)" Name="q24BM_a"><Title LanguageId="11274">q24BM_a</Title><Text LanguageId="11274">BMN-673</Text></Single><Single ObjectId="(0:0-230056026#611777334, 164)" Name="q24BM_b"><Title LanguageId="11274">q24BM_b</Title><Text LanguageId="11274">Niraparib</Text></Single></Nodes></Grid3D><Single ObjectId="(0:0-230056069#578246374, 164)" Name="q24aBM"><Title LanguageId="11274">q24aBM</Title><Text LanguageId="11274">How widely available are BRCA mutation tests currently in your country?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230056079#578246400, 207)" Precode="1"><Text LanguageId="11274">Widely available, with many testing sites throughout the country equipped with the technology</Text></Answer><Answer ObjectId="(0:0-230056080#578246405, 207)" Precode="2"><Text LanguageId="11274">Somewhat available, with some remote testing sites outside the major cities/hospitals</Text></Answer><Answer ObjectId="(0:0-230056081#578246410, 207)" Precode="3"><Text LanguageId="11274">Somewhat unavailable, with testing sites only availably in the major cities/hospitals</Text></Answer><Answer ObjectId="(0:0-230056082#578246415, 207)" Precode="4"><Text LanguageId="11274">Widely unavailable, with almost no testing sites in my country</Text></Answer></Answers></Single><Single ObjectId="(0:0-230056097#578246459, 164)" Name="q25BM"><Title LanguageId="11274">q25BM</Title><Text LanguageId="11274">In your opinion, how easy will it be to incorporate BRCA testing in your routine practice?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230056107#578246485, 207)" Precode="1"><Text LanguageId="11274">Very easy, I consider testing for BRCA mutation as important as testing for HER2 mutation and I do not predict coverage/funding restrictions for BMN-673 and/or niraparib upon BRCA testing</Text></Answer><Answer ObjectId="(0:0-230056108#578246490, 207)" Precode="2"><Text LanguageId="11274">Easy, I do not predict coverage/funding restrictions for BMN-673 and/or niraparib upon BRCA testing, but I only predict to test for BRCA mutation in a subpopulation of patients (e.g., patients with a family history of the disease)</Text></Answer><Answer ObjectId="(0:0-230056109#578246495, 207)" Precode="3"><Text LanguageId="11274">Difficult, I predict that the difficulty in defining a sub-population for the test will raise coverage/funding restrictions for BMN-673 and/or niraparib</Text></Answer><Answer ObjectId="(0:0-230056110#578246500, 207)" Precode="4"><Text LanguageId="11274">Very difficult, I expect severe coverage/funding restrictions for BMN-673 and/or niraparib upon BRCA testing in any condition</Text></Answer></Answers></Single><Grid3D ObjectId="(0:0-230056131#578246573, 204)" Name="q26aBM"><Title LanguageId="11274">q26aBM</Title><Text LanguageId="11274">For what percentage of your non-small cell lung cancer (NSCLC) &lt;u&gt;public patients&lt;/u&gt; with advanced/metastatic disease of each listed histology do you currently send tumor tissue for testing for the following molecular characteristics?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230056191#602269716, 207)" Precode="1"><Text LanguageId="11274">EGFR mutation</Text></Answer><Answer ObjectId="(0:0-230056192#602269721, 207)" Precode="2"><Text LanguageId="11274">ALK translocation</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056133#578246578, 164)" Name="q26aBM_a"><Title LanguageId="11274">q26aBM_a</Title><Text LanguageId="11274">Adenocarcinoma</Text></Multi><Multi ObjectId="(0:0-230056149#578246618, 164)" Name="q26aBM_b"><Title LanguageId="11274">q26aBM_b</Title><Text LanguageId="11274">Large-cell/other</Text></Multi><Multi ObjectId="(0:0-230056165#602269648, 164)" Name="q26aBM_c"><Title LanguageId="11274">q26aBM_c</Title><Text LanguageId="11274">Squamous-cell</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056208#602269762, 204)" Name="q26bBM"><Title LanguageId="11274">q26bBM</Title><Text LanguageId="11274">For what percentage of your non-small cell lung cancer (NSCLC) &lt;u&gt;private patients&lt;/u&gt; with advanced/metastatic disease of each listed histology do you currently send tumor tissue for testing for the following molecular characteristics (independent of receiving definitive results)?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230056268#578253256, 207)" Precode="1"><Text LanguageId="11274">EGFR mutation</Text></Answer><Answer ObjectId="(0:0-230056269#578253261, 207)" Precode="2"><Text LanguageId="11274">ALK translocation</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056210#602269767, 164)" Name="q26bBM_a"><Title LanguageId="11274">q26bBM_a</Title><Text LanguageId="11274">Adenocarcinoma</Text></Multi><Multi ObjectId="(0:0-230056226#602269807, 164)" Name="q26bBM_b"><Title LanguageId="11274">q26bBM_b</Title><Text LanguageId="11274">Large-cell/other</Text></Multi><Multi ObjectId="(0:0-230056242#602269847, 164)" Name="q26bBM_c"><Title LanguageId="11274">q26bBM_c</Title><Text LanguageId="11274">Squamous-cell</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056282#578253291, 204)" Name="q26cBM"><Title LanguageId="11274">q26cBM</Title><Text LanguageId="11274">For what percentage of all your advanced/metastatic NSCLC patients whose tumor tissue is currently sent for molecular testing do you receive a conclusive test result?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230056326#578253496, 207)" Precode="1"><Text LanguageId="11274">EGFR mutation</Text></Answer><Answer ObjectId="(0:0-230056327#578253501, 207)" Precode="2"><Text LanguageId="11274">ALK translocation</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056284#578253298, 164)" Name="q26cBM_a"><Title LanguageId="11274">q26cBM_a</Title><Text LanguageId="11274">Public patients</Text></Multi><Multi ObjectId="(0:0-230056300#578253384, 164)" Name="q26cBM_b"><Title LanguageId="11274">q26cBM_b</Title><Text LanguageId="11274">Private patients</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056340#578253530, 204)" Name="q26dBM"><Title LanguageId="11274">q26dBM</Title><Text LanguageId="11274">What is the average time taken before you receive molecular test results?</Text><Instruction LanguageId="11274">Enter whole numbers of days.</Instruction><Answers><Answer ObjectId="(0:0-230056384#578252164, 207)" Precode="1"><Text LanguageId="11274">EGFR mutation</Text></Answer><Answer ObjectId="(0:0-230056385#578252169, 207)" Precode="2"><Text LanguageId="11274">ALK translocation</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056342#578253535, 164)" Name="q26dBM_a"><Title LanguageId="11274">q26dBM_a</Title><Text LanguageId="11274">Public patients</Text></Multi><Multi ObjectId="(0:0-230056358#578252082, 164)" Name="q26dBM_b"><Title LanguageId="11274">q26dBM_b</Title><Text LanguageId="11274">Private patients</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056398#578252199, 204)" Name="q26eBM"><Title LanguageId="11274">q26eBM</Title><Text LanguageId="11274">In which order to you typically request molecular testing for EGFR mutation and ALK translocation, or do you request both tests simultaneously?</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230056442#578252315, 207)" Precode="1"><Text LanguageId="11274">EGFR test first</Text></Answer><Answer ObjectId="(0:0-230056443#578252320, 207)" Precode="2"><Text LanguageId="11274">ALK test first</Text></Answer><Answer ObjectId="(0:0-230056444#578252325, 207)" Precode="3"><Text LanguageId="11274">EGFR and ALK test simultaneously</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230056400#578252206, 164)" Name="q26eBM_a"><Title LanguageId="11274">q26eBM_a</Title><Text LanguageId="11274">Public Patients</Text></Single><Single ObjectId="(0:0-230056416#578252247, 164)" Name="q26eBM_b"><Title LanguageId="11274">q26eBM_b</Title><Text LanguageId="11274">Private Patients</Text></Single></Nodes></Grid3D><Page ObjectId="(0:0-230056459#578242001, 182)" Name="Copy of Page63"><Nodes><Info ObjectId="(0:0-230056461#578242007, 164)" Name="q27BM"><Title LanguageId="11274">q27BM</Title><Text LanguageId="11274">What most restricts your testing for EGFR mutations and/or ALK translocations in NSCLC patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason OR select Nothing restricts testing, it is entirely my decision.</Instruction></Info><Multi ObjectId="(0:0-230056472#578242037, 164)" Name="q27aBM"><Title LanguageId="11274">q27aBM</Title><Text LanguageId="11274">EGFR mutation</Text><Answers><Answer ObjectId="(0:0-230056482#578242086, 207)" Precode="1"><Text LanguageId="11274">Lack of coverage for the test</Text></Answer><Answer ObjectId="(0:0-230056483#578242091, 207)" Precode="2"><Text LanguageId="11274">Hospital/clinic restrict patient criteria for screening</Text></Answer><Answer ObjectId="(0:0-230056484#578242096, 207)" Precode="3"><Text LanguageId="11274">Patient out of pocket costs</Text></Answer><Answer ObjectId="(0:0-230056485#578242101, 207)" Precode="4"><Text LanguageId="11274">Access to testing facilities</Text></Answer><Answer ObjectId="(0:0-230056486#578242106, 207)" Precode="5"><Text LanguageId="11274">Need to treat before test results are available</Text></Answer><Answer ObjectId="(0:0-230056487#578242111, 207)" Precode="6"><Text LanguageId="11274">Lack of availability of tissue for testing/would require rebiopsy</Text></Answer><Answer ObjectId="(0:0-230056488#578242116, 207)" Precode="7"><Text LanguageId="11274">Restricted access to targeted drug (i.e. Xalkori, Iressa, Tarceva)</Text></Answer><Answer ObjectId="(0:0-230056489#578242121, 207)" Precode="8"><Text LanguageId="11274">Presence of clinical characteristics considered predictive of EGFR mutation (tumor histology, smoking status, gender, and/or ethnicity) negate the need for testing</Text></Answer><Answer ObjectId="(0:0-230056490#578242126, 207)" Precode="9"><Text LanguageId="11274">Absence of clinical characteristics considered predictive of EGFR mutation negate the need for testing</Text></Answer><Answer ObjectId="(0:0-230056491#578242131, 207)" Precode="10"><Text LanguageId="11274">The mutation/translocation occurs in too few patients to justify the cost/time taken to test</Text></Answer><Answer ObjectId="(0:0-230056492#578242136, 207)" Precode="11"><Text LanguageId="11274">Patient denies being tested</Text></Answer><Answer ObjectId="(0:0-230056493#578242141, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230056524#578242229, 164)" Name="q27bBM"><Title LanguageId="11274">q27bBM</Title><Text LanguageId="11274">EGFR mutation</Text><Answers><Answer ObjectId="(0:0-230056534#578242260, 207)" Precode="99"><Text LanguageId="11274">Nothing restricts testing, it is entirely my decision</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230056543#578242282, 164)" Name="q27cBM"><Title LanguageId="11274">q27cBM</Title><Text LanguageId="11274">ALK translocation</Text><Answers><Answer ObjectId="(0:0-230056553#578242331, 207)" Precode="1"><Text LanguageId="11274">Lack of coverage for the test</Text></Answer><Answer ObjectId="(0:0-230056554#578242336, 207)" Precode="2"><Text LanguageId="11274">Hospital/clinic restrict patient criteria for screening</Text></Answer><Answer ObjectId="(0:0-230056555#578242341, 207)" Precode="3"><Text LanguageId="11274">Patient out of pocket costs</Text></Answer><Answer ObjectId="(0:0-230056556#578242346, 207)" Precode="4"><Text LanguageId="11274">Access to testing facilities</Text></Answer><Answer ObjectId="(0:0-230056557#578242351, 207)" Precode="5"><Text LanguageId="11274">Need to treat before test results are available</Text></Answer><Answer ObjectId="(0:0-230056558#578242356, 207)" Precode="6"><Text LanguageId="11274">Lack of availability of tissue for testing/would require rebiopsy</Text></Answer><Answer ObjectId="(0:0-230056559#578242361, 207)" Precode="7"><Text LanguageId="11274">Restricted access to targeted drug (i.e. Xalkori, Iressa, Tarceva)</Text></Answer><Answer ObjectId="(0:0-230056560#578242366, 207)" Precode="8"><Text LanguageId="11274">Presence of clinical characteristics considered predictive of EGFR mutation (tumor histology, smoking status, gender, and/or ethnicity) negate the need for testing</Text></Answer><Answer ObjectId="(0:0-230056561#578242371, 207)" Precode="9"><Text LanguageId="11274">Absence of clinical characteristics considered predictive of EGFR mutation negate the need for testing</Text></Answer><Answer ObjectId="(0:0-230056562#578242376, 207)" Precode="10"><Text LanguageId="11274">The mutation/translocation occurs in too few patients to justify the cost/time taken to test</Text></Answer><Answer ObjectId="(0:0-230056563#578242381, 207)" Precode="11"><Text LanguageId="11274">Patient denies being tested</Text></Answer><Answer ObjectId="(0:0-230056564#578242386, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230056595#578248650, 164)" Name="q27dBM"><Title LanguageId="11274">q27dBM</Title><Text LanguageId="11274">ALK translocation</Text><Answers><Answer ObjectId="(0:0-230056605#578248681, 207)" Precode="99"><Text LanguageId="11274">Nothing restricts testing, it is entirely my decision</Text></Answer></Answers></Multi></Nodes></Page><Grid3D ObjectId="(0:0-230056619#578248720, 204)" Name="q28BM"><Title LanguageId="11274">q28BM</Title><Text LanguageId="11274">What percentage of your non-squamous advanced/metastatic NSCLC patients are harboring the following mutations?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230056663#578248914, 207)" Precode="1"><Text LanguageId="11274">EGFR mutation</Text></Answer><Answer ObjectId="(0:0-230056664#578248919, 207)" Precode="2"><Text LanguageId="11274">ALK translocation</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056621#578248727, 164)" Name="q28aBM"><Title LanguageId="11274">q28aBM</Title><Text LanguageId="11274">% public patients</Text></Multi><Multi ObjectId="(0:0-230056637#578248808, 164)" Name="q28bBM"><Title LanguageId="11274">q28bBM</Title><Text LanguageId="11274">% private patients</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056677#578248948, 204)" Name="q29BM"><Title LanguageId="11274">q29BM</Title><Text LanguageId="11274">What percentages of your advanced/metastatic NSCLC public patients in each subpopulation currently receive drug treatment in each indicated setting?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230056721#578249289, 207)" Precode="1"><Text LanguageId="11274">First-line</Text></Answer><Answer ObjectId="(0:0-230056722#578249294, 207)" Precode="2"><Text LanguageId="11274">Maintenance therapy</Text></Answer><Answer ObjectId="(0:0-230056723#578249299, 207)" Precode="3"><Text LanguageId="11274">Second-line</Text></Answer><Answer ObjectId="(0:0-230056724#578249304, 207)" Precode="4"><Text LanguageId="11274">Third-line</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056679#578248953, 164)" Name="q29BM_a"><Title LanguageId="11274">q29BM_a</Title><Text LanguageId="11274">Non-squamous</Text></Multi><Multi ObjectId="(0:0-230056695#578249222, 164)" Name="q29BM_b"><Title LanguageId="11274">q29BM_b</Title><Text LanguageId="11274">Squamous</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056741#578249341, 204)" Name="q29aBM"><Title LanguageId="11274">q29aBM</Title><Text LanguageId="11274">What percentages of your advanced/metastatic NSCLC private patients in each subpopulation currently receive drug treatment in each indicated setting?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction><Answers><Answer ObjectId="(0:0-230056785#578249455, 207)" Precode="1"><Text LanguageId="11274">First-line</Text></Answer><Answer ObjectId="(0:0-230056786#578249460, 207)" Precode="2"><Text LanguageId="11274">Maintenance therapy</Text></Answer><Answer ObjectId="(0:0-230056787#578249465, 207)" Precode="3"><Text LanguageId="11274">Second-line</Text></Answer><Answer ObjectId="(0:0-230056788#578249470, 207)" Precode="4"><Text LanguageId="11274">Third-line</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056743#578249348, 164)" Name="q29aBM_a"><Title LanguageId="11274">q29aBM_a</Title><Text LanguageId="11274">Non-squamous</Text></Multi><Multi ObjectId="(0:0-230056759#578249388, 164)" Name="q29aBM_b"><Title LanguageId="11274">q29aBM_b</Title><Text LanguageId="11274">Squamous</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056808#578251529, 204)" Name="q30BM"><Title LanguageId="11274">q30BM</Title><Text LanguageId="11274">What percentage of your first-line drug-treated non-squamous NSCLC public patients, in each subpopulation receives the following targeted agents (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q30aBM_3&quot;) != null)
document.getElementById(&quot;q30aBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q30bBM_1&quot;) != null)
document.getElementById(&quot;q30bBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q30bBM_2&quot;) != null)
document.getElementById(&quot;q30bBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q30bBM_6&quot;) != null)
document.getElementById(&quot;q30bBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Must sum to 100%.</Instruction><Answers><Answer ObjectId="(0:0-230056852#578251688, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230056853#578251693, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230056854#578251698, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230056855#578251703, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230056856#578251708, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off-label)</Text></Answer><Answer ObjectId="(0:0-230056857#578251713, 207)" Precode="6"><Text LanguageId="11274">Afatinib (Gilotrif/Giotrif)</Text></Answer><Answer ObjectId="(0:0-230056858#578251718, 207)" Precode="7"><Text LanguageId="11274">Not receiving any targeted agent (racotumomab [Vaxira] only)</Text></Answer><Answer ObjectId="(0:0-230056859#578251723, 207)" Precode="8"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056810#578251537, 164)" Name="q30aBM"><Title LanguageId="11274">q30aBM</Title><Text LanguageId="11274">EGFR-mutated</Text></Multi><Multi ObjectId="(0:0-230056826#578251591, 164)" Name="q30bBM"><Title LanguageId="11274">q30bBM</Title><Text LanguageId="11274">ALK translocation-positive</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056884#578251786, 204)" Name="q31BM"><Title LanguageId="11274">q31BM</Title><Text LanguageId="11274">Among your drug-treated non-squamous NSCLC public patients please select your most frequently prescribed targeted agent in the second- and third- lines of therapy.

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q31aBM_3&quot;) != null)
document.getElementById(&quot;q31aBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q31bBM_1&quot;) != null)
document.getElementById(&quot;q31bBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q31bBM_2&quot;) != null)
document.getElementById(&quot;q31bBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q31bBM_6&quot;) != null)
document.getElementById(&quot;q31bBM_6&quot;).disabled = true;


if(document.getElementById(&quot;q31cBM_3&quot;) != null)
document.getElementById(&quot;q31cBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q31dBM_1&quot;) != null)
document.getElementById(&quot;q31dBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q31dBM_2&quot;) != null)
document.getElementById(&quot;q31dBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q31dBM_6&quot;) != null)
document.getElementById(&quot;q31dBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230056960#578241415, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230056961#578241420, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230056962#578241425, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230056963#578241430, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230056964#578241435, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off-label)</Text></Answer><Answer ObjectId="(0:0-230056965#578241440, 207)" Precode="6"><Text LanguageId="11274">Afatinib (Gilotrif/Giotrif)</Text></Answer><Answer ObjectId="(0:0-230056966#578241445, 207)" Precode="7"><Text LanguageId="11274">None of these</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230056886#578251791, 164)" Name="q31aBM"><Title LanguageId="11274">q31aBM</Title><Text LanguageId="11274">Second-line EGFR-mutated</Text></Single><Single ObjectId="(0:0-230056902#578241249, 164)" Name="q31bBM"><Title LanguageId="11274">q31bBM</Title><Text LanguageId="11274">Second-line ALK translocation-positive</Text></Single><Single ObjectId="(0:0-230056918#578241286, 164)" Name="q31cBM"><Title LanguageId="11274">q31cBM</Title><Text LanguageId="11274">Third-line EGFR-mutated</Text></Single><Single ObjectId="(0:0-230056934#578241323, 164)" Name="q31dBM"><Title LanguageId="11274">q31dBM</Title><Text LanguageId="11274">Third-line ALK translocation-positive</Text></Single></Nodes></Grid3D><Grid3D ObjectId="(0:0-230056992#581280242, 204)" Name="q33BM"><Title LanguageId="11274">q33BM</Title><Text LanguageId="11274">What percentage of your first-line drug-treated non-squamous NSCLC private patients, in each subpopulation receives the following targeted agents (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q33aBM_3&quot;) != null)
document.getElementById(&quot;q33aBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q33aBM_6&quot;) != null)
document.getElementById(&quot;q33aBM_6&quot;).disabled = true;

if(document.getElementById(&quot;q33bBM_1&quot;) != null)
document.getElementById(&quot;q33bBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q33bBM_2&quot;) != null)
document.getElementById(&quot;q33bBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q33bBM_6&quot;) != null)
document.getElementById(&quot;q33bBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Must sum to 100%.</Instruction><Answers><Answer ObjectId="(0:0-230057036#581280404, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230057037#581280409, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230057038#581280414, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230057039#581280419, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230057040#581280424, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off-label)</Text></Answer><Answer ObjectId="(0:0-230057041#581280429, 207)" Precode="6"><Text LanguageId="11274">Afatinib (Gilotrif/Giotrif)</Text></Answer><Answer ObjectId="(0:0-230057042#581280434, 207)" Precode="7"><Text LanguageId="11274">Not receiving any targeted agent (racotumomab [Vaxira] only)</Text></Answer><Answer ObjectId="(0:0-230057043#581280439, 207)" Precode="8"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230056994#581280250, 164)" Name="q33aBM"><Title LanguageId="11274">q33aBM</Title><Text LanguageId="11274">EGFR-mutated</Text></Multi><Multi ObjectId="(0:0-230057010#581280303, 164)" Name="q33bBM"><Title LanguageId="11274">q33bBM</Title><Text LanguageId="11274">ALK translocation-positive</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230057068#581280502, 204)" Name="q34BM"><Title LanguageId="11274">q34BM</Title><Text LanguageId="11274">Among your drug-treated non-squamous NSCLC private patients please select your most frequently prescribed targeted agent in the second- and third- lines of therapy.

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q34aBM_3&quot;) != null)
document.getElementById(&quot;q34aBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q34bBM_1&quot;) != null)
document.getElementById(&quot;q34bBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q34bBM_2&quot;) != null)
document.getElementById(&quot;q34bBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q34bBM_6&quot;) != null)
document.getElementById(&quot;q34bBM_6&quot;).disabled = true;


if(document.getElementById(&quot;q34cBM_3&quot;) != null)
document.getElementById(&quot;q34cBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q34dBM_1&quot;) != null)
document.getElementById(&quot;q34dBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q34dBM_2&quot;) != null)
document.getElementById(&quot;q34dBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q34dBM_6&quot;) != null)
document.getElementById(&quot;q34dBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230057144#578244845, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230057145#578244850, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230057146#578244855, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230057147#578244860, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230057148#578244865, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off-label)</Text></Answer><Answer ObjectId="(0:0-230057149#578244870, 207)" Precode="6"><Text LanguageId="11274">Afatinib (Gilotrif/Giotrif)</Text></Answer><Answer ObjectId="(0:0-230057150#578244875, 207)" Precode="7"><Text LanguageId="11274">None of these</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230057070#581280507, 164)" Name="q34aBM"><Title LanguageId="11274">q34aBM</Title><Text LanguageId="11274">Second-line EGFR-mutated</Text></Single><Single ObjectId="(0:0-230057086#578244679, 164)" Name="q34bBM"><Title LanguageId="11274">q34bBM</Title><Text LanguageId="11274">Second-line ALK translocation-positive</Text></Single><Single ObjectId="(0:0-230057102#578244716, 164)" Name="q34cBM"><Title LanguageId="11274">q34cBM</Title><Text LanguageId="11274">Third-line EGFR-mutated</Text></Single><Single ObjectId="(0:0-230057118#578244753, 164)" Name="q34dBM"><Title LanguageId="11274">q34dBM</Title><Text LanguageId="11274">Third-line ALK translocation-positive</Text></Single></Nodes></Grid3D><Page ObjectId="(0:0-230057173#578238961, 182)" Name="Page54"><Nodes><Grid3D ObjectId="(0:0-230057175#578238967, 204)" Name="q39BM"><Title LanguageId="11274">q39BM</Title><Text LanguageId="11274">If all of the following treatments were approved by the regulatory agencies in your country and 100% funded/covered/ reimbursed for advanced/metastatic NSCLC by the patient’s health insurance plan and/or by the government or ^f('Sq1').get() == '1' ? &quot;Social Security&quot; : &quot;the Obras Sociales&quot;^, which one would you primarily consider prescribing in each subpopulation (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q39aBM_3&quot;) != null)
document.getElementById(&quot;q39aBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q39bBM_1&quot;) != null)
document.getElementById(&quot;q39bBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q39bBM_2&quot;) != null)
document.getElementById(&quot;q39bBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q39bBM_6&quot;) != null)
document.getElementById(&quot;q39bBM_6&quot;).disabled = true;


if(document.getElementById(&quot;q39cBM_3&quot;) != null)
document.getElementById(&quot;q39cBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q39dBM_1&quot;) != null)
document.getElementById(&quot;q39dBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q39dBM_2&quot;) != null)
document.getElementById(&quot;q39dBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q39dBM_6&quot;) != null)
document.getElementById(&quot;q39dBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230057251#578239182, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230057252#578239187, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230057253#578239192, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230057254#578239197, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230057255#578239202, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off-label)</Text></Answer><Answer ObjectId="(0:0-230057256#578239207, 207)" Precode="6"><Text LanguageId="11274">Gilotrif/Giotrif (afatinib)</Text></Answer><Answer ObjectId="(0:0-230057257#578239212, 207)" Precode="7"><Text LanguageId="11274">None of these agents (racotumomab [Vaxira] only]</Text></Answer><Answer ObjectId="(0:0-230057258#578239217, 207)" Precode="8"><Text LanguageId="11274">None of these agents (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230057259#578239222, 207)" Precode="98"><Text LanguageId="11274">Other</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230057177#578238975, 164)" Name="q39aBM"><Title LanguageId="11274">q39aBM</Title><Text LanguageId="11274">Non-squamous EGFR-mutated</Text></Single><Single ObjectId="(0:0-230057193#578239011, 164)" Name="q39bBM"><Title LanguageId="11274">q39bBM</Title><Text LanguageId="11274">Non-squamous ALK translocation-positive</Text></Single><Single ObjectId="(0:0-230057209#578239047, 164)" Name="q39cBM"><Title LanguageId="11274">q39cBM</Title><Text LanguageId="11274">Squamous EGFR-mutated</Text></Single><Single ObjectId="(0:0-230057225#578239083, 164)" Name="q39dBM"><Title LanguageId="11274">q39dBM</Title><Text LanguageId="11274">Squamous ALK translocation-positive</Text></Single></Nodes></Grid3D><Open ObjectId="(0:0-230057283#611777456, 164)" Name="q39aBM_Other"><Title LanguageId="11274">q39aBM_Other</Title><Text LanguageId="11274">Please specify the Other for Non-squamous EGFR-mutated.</Text></Open><Open ObjectId="(0:0-230057295#611777486, 164)" Name="q39bBM_Other"><Title LanguageId="11274">q39bBM_Other</Title><Text LanguageId="11274">Please specify the Other for Non-squamous ALK translocation-positive.</Text></Open><Open ObjectId="(0:0-230057307#611777516, 164)" Name="q39cBM_Other"><Title LanguageId="11274">q39cBM_Other</Title><Text LanguageId="11274">Please specify the Other for Squamous EGFR-mutated.</Text></Open><Open ObjectId="(0:0-230057319#611777546, 164)" Name="q39dBM_Other"><Title LanguageId="11274">q39dBM_Other</Title><Text LanguageId="11274">Please specify the Other for Squamous ALK translocation-positive.</Text></Open></Nodes></Page><Info ObjectId="(0:0-230057333#611777580, 164)" Name="Ceritinib"><Title LanguageId="11274">Ceritinib</Title><Text LanguageId="11274">&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt; mso-add-space: auto&quot; class=&quot;MsoListParagraphCxSpFirst&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;A second-generation ALK inhibitor is in development, &lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;ceritinib&lt;/b&gt;:&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;table style=&quot;border-bottom: medium none; border-left: medium none; margin: auto auto auto 6.85pt; border-collapse: collapse; border-top: medium none; border-right: medium none; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-alt: solid windowtext .5pt; mso-yfti-tbllook: 1184&quot; class=&quot;MsoTableGrid&quot; border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;&lt;tbody&gt;&lt;tr style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 404pt; padding-right: 5.4pt; background: #bdd6ee; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0in; mso-border-alt: solid windowtext .5pt; mso-background-themecolor: accent1; mso-background-themetint: 102&quot; valign=&quot;top&quot; width=&quot;539&quot;&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri&quot;&gt;Novartis’ ceritinib (&lt;/span&gt;&lt;/b&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;LDK378)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=&quot;height: 49.6pt; mso-yfti-irow: 1; mso-yfti-lastrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; background-color: transparent; padding-left: 5.4pt; width: 404pt; padding-right: 5.4pt; height: 49.6pt; border-top: #f0f0f0; border-right: windowtext 1pt solid; padding-top: 0in; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt&quot; valign=&quot;top&quot; width=&quot;539&quot;&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri&quot;&gt;Dosing:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri&quot;&gt; 750 mg (oral) daily&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri&quot;&gt;Development status:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: calibri&quot;&gt; 1 ongoing phase III trial in your country&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;span style=&quot;mso-tab-count: 1&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;Paragraph&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;u&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;font size=&quot;2&quot;&gt;Phase I data (&lt;i style=&quot;mso-bidi-font-style: normal&quot;&gt;ALK&lt;/i&gt;-positive patients as determined by FISH, n = 131)&lt;p&gt;&lt;/p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;Paragraph&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;font size=&quot;2&quot;&gt;All patients, Xalkori-na&#239;ve and Xalkori pretreated (n = 123):&lt;p&gt;&lt;/p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: 0in; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1&quot; class=&quot;Paragraph&quot;&gt;&lt;span style=&quot;font-family: symbol; mso-bidi-font-weight: bold; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&lt;font size=&quot;2&quot;&gt;&#183;&lt;/font&gt;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; mso-bidi-font-weight: bold&quot;&gt;&lt;font size=&quot;2&quot;&gt;PFS: 8.6 months&lt;p&gt;&lt;/p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;Paragraph&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;font size=&quot;2&quot;&gt;Patients evaluable for tumor response:&lt;p&gt;&lt;/p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: 0in; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1&quot; class=&quot;Paragraph&quot;&gt;&lt;span style=&quot;font-family: symbol; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&lt;font size=&quot;2&quot;&gt;&#183;&lt;/font&gt;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;font size=&quot;2&quot;&gt;ORR: 70% (88 evaluable patients); 73% (64 patients with &lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;Xalkori-resistant&lt;/b&gt; mutations)&lt;p&gt;&lt;/p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: 0in; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1&quot; class=&quot;Paragraph&quot;&gt;&lt;span style=&quot;font-family: symbol; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&lt;font size=&quot;2&quot;&gt;&#183;&lt;/font&gt;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;font size=&quot;2&quot;&gt;Duration of response: 7.4 months&lt;/font&gt;&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;Paragraph&quot;&gt;&lt;font size=&quot;2&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;Most common adverse events: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;&quot;&gt;Nausea (72%), diarrhea (69%), vomiting (50%), and fatigue (31%).&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;Most common grade 3/4 adverse events: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;A&lt;span style=&quot;mso-bidi-font-style: italic&quot;&gt;lanine&lt;/span&gt; aminotransferase (ALT) elevation (12%), diarrhea (7%), and &lt;span style=&quot;mso-bidi-font-style: italic&quot;&gt;aspartate transaminase&lt;/span&gt; (AST) elevation (6%). &lt;/span&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;br&gt;Expected Launch Date:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt; 2015&lt;br&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</Text></Info><Multi ObjectId="(0:0-230057347#611777893, 164)" Name="q40BM"><Title LanguageId="11274">q40BM</Title><Text LanguageId="11274">Which of the following statements do you agree with when considering ceritinib for your non-squamous ALK translocation-positive advanced/metastatic NSCLC patients, by the end of 2017, assuming this treatment is approved and launched in your country?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230057357#611777922, 207)" Precode="1"><Text LanguageId="11274">Improved mechanism of action (over Xalkori)</Text></Answer><Answer ObjectId="(0:0-230057358#611777927, 207)" Precode="2"><Text LanguageId="11274">Greater efficacy</Text></Answer><Answer ObjectId="(0:0-230057359#611777932, 207)" Precode="3"><Text LanguageId="11274">Higher response rate</Text></Answer><Answer ObjectId="(0:0-230057360#611777937, 207)" Precode="4"><Text LanguageId="11274">Improved tolerability</Text></Answer><Answer ObjectId="(0:0-230057361#611777942, 207)" Precode="5"><Text LanguageId="11274">Reduced toxicity</Text></Answer><Answer ObjectId="(0:0-230057362#611777947, 207)" Precode="6"><Text LanguageId="11274">Other (please specify)</Text></Answer><Answer ObjectId="(0:0-230057363#611777952, 207)" Precode="7"><Text LanguageId="11274">I anticipate a favorable environment for inclusion in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230057364#611777957, 207)" Precode="8"><Text LanguageId="11274">I anticipate a favorable environment for inclusion in the private sector hospital/institutional formularies</Text></Answer><Answer ObjectId="(0:0-230057365#611777962, 207)" Precode="99"><Text LanguageId="11274">I do not predict to prescribe this agent</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230057396#598112302, 164)" Name="q41BM"><Title LanguageId="11274">q41BM</Title><Text LanguageId="11274">Which of the following statements do you agree with when NOT considering ceritinib for your non-squamous ALK translocation-positive advanced/metastatic NSCLC patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason, etc.</Instruction><Answers><Answer ObjectId="(0:0-230057406#598112333, 207)" Precode="1"><Text LanguageId="11274">Insufficient data on greater efficacy over Xalkori</Text></Answer><Answer ObjectId="(0:0-230057407#598112338, 207)" Precode="2"><Text LanguageId="11274">I have some concerns regarding the toxicity profile of this drug</Text></Answer><Answer ObjectId="(0:0-230057408#598112343, 207)" Precode="3"><Text LanguageId="11274">Requirement for treatment before mutation test results are known</Text></Answer><Answer ObjectId="(0:0-230057409#598112348, 207)" Precode="4"><Text LanguageId="11274">Greater familiarity with Xalkori</Text></Answer><Answer ObjectId="(0:0-230057410#598112353, 207)" Precode="5"><Text LanguageId="11274">I expect restrictions on the coverage for mutational testing</Text></Answer><Answer ObjectId="(0:0-230057411#598112358, 207)" Precode="6"><Text LanguageId="11274">I do not think that this treatment will be included in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230057412#598112363, 207)" Precode="7"><Text LanguageId="11274">I do not think that this treatment will be covered in private hospitals/institutions</Text></Answer><Answer ObjectId="(0:0-230057413#598112368, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Grid ObjectId="(0:0-230057439#598112445, 164)" Name="q42BM"><Title LanguageId="11274">q42BM</Title><Text LanguageId="11274">Assuming that ceritinib is approved by the regulatory agencies in your country and both Xalkori and ceritinib are 100% funded/covered/reimbursed for advanced/metastatic non-squamous ALK translocation-positive NSCLC patients, which agent would you primarily choose to prescribe in each setting, by the end of 2017?</Text><Instruction LanguageId="11274">Select one per row.</Instruction><Answers><Answer ObjectId="(0:0-230057452#598112486, 207)" Precode="1"><Text LanguageId="11274">As first-line treatment</Text></Answer><Answer ObjectId="(0:0-230057453#598112491, 207)" Precode="2"><Text LanguageId="11274">As prolonged first-line treatment beyond disease progression</Text></Answer><Answer ObjectId="(0:0-230057454#598112496, 207)" Precode="3"><Text LanguageId="11274">As second-line treatment</Text></Answer><Answer ObjectId="(0:0-230057455#598112501, 207)" Precode="4"><Text LanguageId="11274">As prolonged second-line treatment beyond disease progression</Text></Answer><Answer ObjectId="(0:0-230057456#598112506, 207)" Precode="5"><Text LanguageId="11274">As third- or later-line treatment</Text></Answer></Answers><Scales><Scale ObjectId="(0:0-230057467#598112538, 207)" Precode="1"><Text LanguageId="11274">Xalkori</Text></Scale><Scale ObjectId="(0:0-230057468#598112542, 207)" Precode="2"><Text LanguageId="11274">Ceritinib</Text></Scale></Scales></Grid><Grid3D ObjectId="(0:0-230057492#583746686, 204)" Name="q43BM"><Title LanguageId="11274">q43BM</Title><Text LanguageId="11274">Please estimate what proportion of your first-line drug-treated non-squamous NSCLC public patients will be receiving each indicated therapy, by the end of 2017.

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q43bBM_3&quot;) != null)
document.getElementById(&quot;q43bBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q43bBM_8&quot;) != null)
document.getElementById(&quot;q43bBM_8&quot;).disabled = true;

if(document.getElementById(&quot;q43dBM_1&quot;) != null)
document.getElementById(&quot;q43dBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q43dBM_2&quot;) != null)
document.getElementById(&quot;q43dBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q43dBM_6&quot;) != null)
document.getElementById(&quot;q43dBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Must sum to 100%. For your reference, the percentages you estimated for your current use of these treatments are shown below. Please bear in mind:
&lt;p&gt;A.	The expected launch of ceritinib;
&lt;p&gt;B.	Your own clinical experience and preferences, but also your knowledge of the reimbursement/coverage/funding situation in your hospital, region or country.</Instruction><Answers><Answer ObjectId="(0:0-230057568#583746925, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230057569#583746930, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230057570#583746935, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230057571#583746940, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230057572#583746945, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off label)</Text></Answer><Answer ObjectId="(0:0-230057573#583746950, 207)" Precode="6"><Text LanguageId="11274">Gilotrif/Giotrif (afatinib)</Text></Answer><Answer ObjectId="(0:0-230057574#583746955, 207)" Precode="7"><Text LanguageId="11274">Not receiving any targeted agent (racotumomab [Vaxira] only]</Text></Answer><Answer ObjectId="(0:0-230057575#583746960, 207)" Precode="8"><Text LanguageId="11274">Ceritinib</Text></Answer><Answer ObjectId="(0:0-230057576#583746965, 207)" Precode="9"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230057494#583746694, 164)" Name="q43aBM"><Title LanguageId="11274">q43aBM</Title><Text LanguageId="11274">EGFR-mutated - Current</Text></Multi><Multi ObjectId="(0:0-230057510#583746732, 164)" Name="q43bBM"><Title LanguageId="11274">q43bBM</Title><Text LanguageId="11274">EGFR-mutated - 2017</Text></Multi><Multi ObjectId="(0:0-230057526#583746787, 164)" Name="q43cBM"><Title LanguageId="11274">q43cBM</Title><Text LanguageId="11274">ALK translocation-positive - Current</Text></Multi><Multi ObjectId="(0:0-230057542#583746825, 164)" Name="q43dBM"><Title LanguageId="11274">q43dBM</Title><Text LanguageId="11274">ALK translocation-positive - 2017</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230057612#572049398, 204)" Name="q44BM"><Title LanguageId="11274">q44BM</Title><Text LanguageId="11274">Please estimate what proportion of your first-line drug-treated non-squamous NSCLC private patients will be receiving each indicated therapy, by the end of 2017.


&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q44bBM_3&quot;) != null)
document.getElementById(&quot;q44bBM_3&quot;).disabled = true;

if(document.getElementById(&quot;q44bBM_8&quot;) != null)
document.getElementById(&quot;q44bBM_8&quot;).disabled = true;

if(document.getElementById(&quot;q44dBM_1&quot;) != null)
document.getElementById(&quot;q44dBM_1&quot;).disabled = true;

if(document.getElementById(&quot;q44dBM_2&quot;) != null)
document.getElementById(&quot;q44dBM_2&quot;).disabled = true;

if(document.getElementById(&quot;q44dBM_6&quot;) != null)
document.getElementById(&quot;q44dBM_6&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Must sum to 100%. For your reference, the percentages you estimated for your current use of these treatments are shown below. Please bear in mind:
&lt;p&gt;A.	The expected launch of afatinib, dacomitinib and ceritinib;
&lt;p&gt;B.	Your own clinical experience and preferences, but also your knowledge of the reimbursement/funding situation in your hospital, region or country.</Instruction><Answers><Answer ObjectId="(0:0-230057688#572049637, 207)" Precode="1"><Text LanguageId="11274">^f('Sq1').get() == '1' ? &quot;Erlotinib (Tarceva)&quot; : &quot;Erlotinib (Tarceva, Relotib, Terovan)&quot;^</Text></Answer><Answer ObjectId="(0:0-230057689#572049642, 207)" Precode="2"><Text LanguageId="11274">Gefitinib (Iressa)</Text></Answer><Answer ObjectId="(0:0-230057690#572049647, 207)" Precode="3"><Text LanguageId="11274">Crizotinib (Xalkori)</Text></Answer><Answer ObjectId="(0:0-230057691#572049652, 207)" Precode="4"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230057692#572049657, 207)" Precode="5"><Text LanguageId="11274">Cetuximab (Erbitux) (off label)</Text></Answer><Answer ObjectId="(0:0-230057693#572049662, 207)" Precode="6"><Text LanguageId="11274">Gilotrif/Giotrif (afatinib)</Text></Answer><Answer ObjectId="(0:0-230057694#572049667, 207)" Precode="7"><Text LanguageId="11274">Not receiving any targeted agent (racotumomab [Vaxira] only]</Text></Answer><Answer ObjectId="(0:0-230057695#572049672, 207)" Precode="8"><Text LanguageId="11274">Ceritinib</Text></Answer><Answer ObjectId="(0:0-230057696#572049677, 207)" Precode="9"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230057614#572049406, 164)" Name="q44aBM"><Title LanguageId="11274">q44aBM</Title><Text LanguageId="11274">EGFR-mutated - Current</Text></Multi><Multi ObjectId="(0:0-230057630#572049444, 164)" Name="q44bBM"><Title LanguageId="11274">q44bBM</Title><Text LanguageId="11274">EGFR-mutated - 2017</Text></Multi><Multi ObjectId="(0:0-230057646#572049499, 164)" Name="q44cBM"><Title LanguageId="11274">q44cBM</Title><Text LanguageId="11274">ALK translocation-positive - Current</Text></Multi><Multi ObjectId="(0:0-230057662#572049537, 164)" Name="q44dBM"><Title LanguageId="11274">q44dBM</Title><Text LanguageId="11274">ALK translocation-positive - 2017</Text></Multi></Nodes></Grid3D><Page ObjectId="(0:0-230057723#598919579, 182)" Name="Page55"><Nodes><Info ObjectId="(0:0-230057725#598919585, 164)" Name="q46BM"><Title LanguageId="11274">q46BM</Title><Text LanguageId="11274">For what percentage of your metastatic colorectal cancer (mCRC) patients do you currently send tumor tissue for testing KRAS mutation?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction></Info><Open ObjectId="(0:0-230057736#598919613, 164)" Name="q46aBM"><Title LanguageId="11274">q46aBM</Title><Text LanguageId="11274">% of public patients</Text></Open><Open ObjectId="(0:0-230057748#598919645, 164)" Name="q46bBM"><Title LanguageId="11274">q46bBM</Title><Text LanguageId="11274">% of private patients</Text></Open></Nodes></Page><Grid3D ObjectId="(0:0-230057766#598919690, 204)" Name="q47aBM"><Title LanguageId="11274">q47aBM</Title><Text LanguageId="11274">When do you typically test your mCRC patients for KRAS mutation?</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230057810#598919795, 207)" Precode="1"><Text LanguageId="11274">Before initiation of first-line treatment</Text></Answer><Answer ObjectId="(0:0-230057811#598919800, 207)" Precode="2"><Text LanguageId="11274">After initiation of first-line treatment but before second-line treatment</Text></Answer><Answer ObjectId="(0:0-230057812#598919805, 207)" Precode="3"><Text LanguageId="11274">After initiation of second but before third-line treatment</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230057768#598919697, 164)" Name="q47aBM_a"><Title LanguageId="11274">q47aBM_a</Title><Text LanguageId="11274">Public patients</Text></Single><Single ObjectId="(0:0-230057784#598919734, 164)" Name="q47aBM_b"><Title LanguageId="11274">q47aBM_b</Title><Text LanguageId="11274">Private patients</Text></Single></Nodes></Grid3D><Page ObjectId="(0:0-230057824#581278501, 182)" Name="Copy of Page55"><Nodes><Info ObjectId="(0:0-230057826#581278507, 164)" Name="q47bBM"><Title LanguageId="11274">q47bBM</Title><Text LanguageId="11274">For what percentage of all your mCRC patients whose tumor tissue is currently sent for molecular testing do you receive a conclusive test result?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction></Info><Open ObjectId="(0:0-230057837#581278536, 164)" Name="q47bBM_a"><Title LanguageId="11274">q47bBM_a</Title><Text LanguageId="11274">Public patients</Text></Open><Open ObjectId="(0:0-230057849#581278569, 164)" Name="q47bBM_b"><Title LanguageId="11274">q47bBM_b</Title><Text LanguageId="11274">Private patients</Text></Open></Nodes></Page><Page ObjectId="(0:0-230057866#581278614, 182)" Name="Copy of Copy of Page55"><Nodes><Info ObjectId="(0:0-230057868#581278620, 164)" Name="q47cBM"><Title LanguageId="11274">q47cBM</Title><Text LanguageId="11274">What is the average time taken before you receive molecular test results?</Text><Instruction LanguageId="11274">Enter whole numbers of days.</Instruction></Info><Open ObjectId="(0:0-230057879#581278646, 164)" Name="q47cBM_a"><Title LanguageId="11274">q47cBM_a</Title><Text LanguageId="11274">Public patients</Text></Open><Open ObjectId="(0:0-230057891#581278679, 164)" Name="q47cBM_b"><Title LanguageId="11274">q47cBM_b</Title><Text LanguageId="11274">Private patients</Text></Open></Nodes></Page><Page ObjectId="(0:0-230057908#581278721, 182)" Name="Copy of Page63"><Nodes><Multi ObjectId="(0:0-230057910#581278727, 164)" Name="q48aBM"><Title LanguageId="11274">q48aBM</Title><Text LanguageId="11274">What most restricts your testing for KRAS mutation in mCRC patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason OR select &quot;Nothing restricts testing, it is entirely my decision.&quot;</Instruction><Answers><Answer ObjectId="(0:0-230057920#581278769, 207)" Precode="1"><Text LanguageId="11274">Lack of coverage for the test</Text></Answer><Answer ObjectId="(0:0-230057921#581278774, 207)" Precode="2"><Text LanguageId="11274">Hospital/clinic restrict patient criteria for screening</Text></Answer><Answer ObjectId="(0:0-230057922#581278779, 207)" Precode="3"><Text LanguageId="11274">Patient out of pocket costs</Text></Answer><Answer ObjectId="(0:0-230057923#581278784, 207)" Precode="4"><Text LanguageId="11274">Access to testing facilities</Text></Answer><Answer ObjectId="(0:0-230057924#581278789, 207)" Precode="5"><Text LanguageId="11274">Need to treat before test results are available</Text></Answer><Answer ObjectId="(0:0-230057925#581278794, 207)" Precode="6"><Text LanguageId="11274">Lack of availability of tissue for testing/would require rebiopsy</Text></Answer><Answer ObjectId="(0:0-230057926#581278799, 207)" Precode="7"><Text LanguageId="11274">Restricted access to targeted drug (i.e. cetuximab [Erbitux], panitumumab [Vectibix])</Text></Answer><Answer ObjectId="(0:0-230057927#581278804, 207)" Precode="8"><Text LanguageId="11274">Molecular results does not impact my treatment decision</Text></Answer><Answer ObjectId="(0:0-230057928#581278809, 207)" Precode="9"><Text LanguageId="11274">The mutation occurs in too few patients to justify the cost/time taken to test</Text></Answer><Answer ObjectId="(0:0-230057929#581278814, 207)" Precode="10"><Text LanguageId="11274">Patient denies being tested</Text></Answer><Answer ObjectId="(0:0-230057930#581278819, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230057959#574784451, 164)" Name="q48bBM"><Title LanguageId="11274">q48bBM</Title><Answers><Answer ObjectId="(0:0-230057969#574784476, 207)" Precode="99"><Text LanguageId="11274">Nothing restricts testing, it is entirely my decision</Text></Answer></Answers></Multi></Nodes></Page><Grid3D ObjectId="(0:0-230057986#574784517, 204)" Name="q49BM"><Title LanguageId="11274">q49BM</Title><Text LanguageId="11274">What percentage of your mCRC public patients with KRAS wild-type receives the following targeted agents (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q49aBM_99&quot;) != null)
document.getElementById(&quot;q49aBM_99&quot;).disabled = true;
document.getElementById(&quot;q49aBM_99&quot;).style.backgroundColor = &quot;#EAEAEA&quot;;
}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Enter whole percentages. Must sum to 100% for each column.</Instruction><Answers><Answer ObjectId="(0:0-230058046#574784734, 207)" Precode="1"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230058047#574784739, 207)" Precode="2"><Text LanguageId="11274">Cetuximab (Erbitux)</Text></Answer><Answer ObjectId="(0:0-230058048#574784744, 207)" Precode="3"><Text LanguageId="11274">Panitumumab (Vectibix)</Text></Answer><Answer ObjectId="(0:0-230058049#574784749, 207)" Precode="4"><Text LanguageId="11274">Regorafenib (Stivarga)</Text></Answer><Answer ObjectId="(0:0-230058050#574784754, 207)" Precode="5"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230058051#574784759, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230057988#574784525, 164)" Name="q49aBM"><Title LanguageId="11274">q49aBM</Title><Text LanguageId="11274">First-line</Text></Multi><Multi ObjectId="(0:0-230058004#574784577, 164)" Name="q49bBM"><Title LanguageId="11274">q49bBM</Title><Text LanguageId="11274">Second-line</Text></Multi><Multi ObjectId="(0:0-230058020#574784639, 164)" Name="q49cBM"><Title LanguageId="11274">q49cBM</Title><Text LanguageId="11274">Third-line</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230058075#578927031, 204)" Name="q50BM"><Title LanguageId="11274">q50BM</Title><Text LanguageId="11274">What percentage of your mCRC private patients with KRAS wild-type receives the following targeted agents (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{
if(document.getElementById(&quot;q50aBM_99&quot;) != null)
document.getElementById(&quot;q50aBM_99&quot;).disabled = true;
document.getElementById(&quot;q50aBM_99&quot;).style.backgroundColor = &quot;#EAEAEA&quot;;
}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Enter whole percentages. Must sum to 100% for each column.</Instruction><Answers><Answer ObjectId="(0:0-230058135#578927248, 207)" Precode="1"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230058136#578927253, 207)" Precode="2"><Text LanguageId="11274">Cetuximab (Erbitux)</Text></Answer><Answer ObjectId="(0:0-230058137#578927258, 207)" Precode="3"><Text LanguageId="11274">Panitumumab (Vectibix)</Text></Answer><Answer ObjectId="(0:0-230058138#578927263, 207)" Precode="4"><Text LanguageId="11274">Regorafenib (Stivarga)</Text></Answer><Answer ObjectId="(0:0-230058139#578927268, 207)" Precode="5"><Text LanguageId="11274">Not receiving any targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230058140#578927273, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230058077#578927039, 164)" Name="q50aBM"><Title LanguageId="11274">q50aBM</Title><Text LanguageId="11274">First-line</Text></Multi><Multi ObjectId="(0:0-230058093#578927091, 164)" Name="q50bBM"><Title LanguageId="11274">q50bBM</Title><Text LanguageId="11274">Second-line</Text></Multi><Multi ObjectId="(0:0-230058109#578927153, 164)" Name="q50cBM"><Title LanguageId="11274">q50cBM</Title><Text LanguageId="11274">Third-line</Text></Multi></Nodes></Grid3D><Grid3D ObjectId="(0:0-230058161#574783889, 204)" Name="q51BM"><Title LanguageId="11274">q51BM</Title><Text LanguageId="11274">If all of the following treatments were approved by the regulatory agencies in your country and 100% funded/covered/ reimbursed for mCRC with KRAS wild-type by the patient’s health insurance plan and/or by the government or ^f('Sq1').get() == '1' ? &quot;Social Security&quot; : &quot;the Obras Sociales&quot;^, which one would you primarily consider prescribing to your patients (+/- chemotherapy)?


&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{

if(document.getElementById(&quot;q51aBM_99&quot;) != null)
document.getElementById(&quot;q51aBM_99&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230058221#574784051, 207)" Precode="1"><Text LanguageId="11274">Bevacizumab (Avastin)</Text></Answer><Answer ObjectId="(0:0-230058222#574784056, 207)" Precode="2"><Text LanguageId="11274">Cetuximab (Erbitux)</Text></Answer><Answer ObjectId="(0:0-230058223#574784061, 207)" Precode="3"><Text LanguageId="11274">Panitumumab (Vectibix)</Text></Answer><Answer ObjectId="(0:0-230058224#574784066, 207)" Precode="4"><Text LanguageId="11274">Regorafenib (Stivarga)</Text></Answer><Answer ObjectId="(0:0-230058225#574784071, 207)" Precode="5"><Text LanguageId="11274">No targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230058226#574784076, 207)" Precode="99"><Text LanguageId="11274">I would not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230058163#574783897, 164)" Name="q51aBM"><Title LanguageId="11274">q51aBM</Title><Text LanguageId="11274">First-line</Text></Single><Single ObjectId="(0:0-230058179#574783941, 164)" Name="q51bBM"><Title LanguageId="11274">q51bBM</Title><Text LanguageId="11274">Second-line</Text></Single><Single ObjectId="(0:0-230058195#574783976, 164)" Name="q51cBM"><Title LanguageId="11274">q51cBM</Title><Text LanguageId="11274">Third-line</Text></Single></Nodes></Grid3D><Info ObjectId="(0:0-230058244#574784121, 164)" Name="Dalotuzumab"><Title LanguageId="11274">Dalotuzumab</Title><Text LanguageId="11274">&lt;p style=&quot;margin: 0in 0in 8pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;line-height: 107%; font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Merck and Pierre Fabre are developing dalotuzumab (IGF-1R targeted monoclonal antibody), currently in a Phase II clinical trial in combination with cetuximab and irinotecan for IGF-1 highly-expressing mCRC.&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;table style=&quot;border-bottom: medium none; border-left: medium none; margin: auto auto auto 21.05pt; width: 382.7pt; border-collapse: collapse; border-top: medium none; border-right: medium none; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-alt: solid black .5pt; mso-border-insideh: .5pt solid black; mso-border-insidev: .5pt solid black&quot; class=&quot;MsoNormalTable&quot; border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;510&quot;&gt;&lt;tbody&gt;&lt;tr style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 382.7pt; padding-right: 5.4pt; background: #c6d9f1; border-top: black 1pt solid; border-right: black 1pt solid; padding-top: 0in; mso-border-alt: solid black .5pt&quot; width=&quot;510&quot;&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt;Merck/Pierre Fabre’s dalotuzumab&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=&quot;height: 35.4pt; mso-yfti-irow: 1; mso-yfti-lastrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0in; background-color: transparent; padding-left: 5.4pt; width: 382.7pt; padding-right: 5.4pt; height: 35.4pt; border-top: #f0f0f0; border-right: black 1pt solid; padding-top: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; valign=&quot;top&quot; width=&quot;510&quot;&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt;Formulation: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt;IV&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt;Development status:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt; Phase II, no clinical trials in your country&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt;&lt;span style=&quot;mso-tab-count: 1&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;u&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;Phase II data:&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;MK-0646-004 trial:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt; in patients that&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt; have failed an irinotecan and an oxaliplatin based regimen (third line) wt KRAS only &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt&quot;&gt;(n=560)&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;Efficacy data:&lt;i style=&quot;mso-bidi-font-style: normal&quot;&gt; &lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;Dalotuzumab (either 10 or 15 mg/kg) + cetuximab + irinotecan vs. placebo + cetuximab + irinotecan; Dalotuzumab 10 mg/kg vs. dalotuzumab 15 mg/kg vs. placebo (primary end points):&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.5in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=&quot;MsoListParagraphCxSpFirst&quot;&gt;&lt;span style=&quot;font-family: symbol; font-size: 10pt; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;PFS: 3.3 vs. 5.4 vs. 5.6 months &lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.5in; mso-add-space: auto; mso-list: l0 level1 lfo1&quot; class=&quot;MsoListParagraphCxSpLast&quot;&gt;&lt;span style=&quot;font-family: symbol; font-size: 10pt; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;OS: 10.8 vs. 11.6 vs. 14.0 months&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt;Safety data:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot;&gt; &lt;u&gt;Dalotuzumab 10 mg/kg vs. placebo:&lt;/u&gt; Weight loss: 22.4% vs.10.8%; Dehydration: 7.8% vs. 1.8%; Hyperglycemia: 33.6% vs. 20.7%; &lt;u&gt;Dalotuzumab 15 mg/kg vs. placebo:&lt;/u&gt; Hyperglycemia: 40.2% vs. 20.7%; Neuropathy: 9.4% vs. 2.7%; Stomatitis: 51.3% vs. 36.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</Text></Info><Single ObjectId="(0:0-230058255#573943910, 164)" Name="q52BM"><Title LanguageId="11274">q52BM</Title><Text LanguageId="11274">Assuming that dalotuzumab is approved by the regulatory agencies in your country for mCRC, how important will approval of a companion biomarker test be in your decision to prescribe this agent?  Please note: Companion biomarkers are biomarkers that are used in combination with specific targeted therapies.</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230058265#573943936, 207)" Precode="1"><Text LanguageId="11274">I will only prescribe if a validated companion biomarker test is available</Text></Answer><Answer ObjectId="(0:0-230058266#573943941, 207)" Precode="2"><Text LanguageId="11274">I am unlikely to prescribe unless a validated companion biomarker test is available</Text></Answer><Answer ObjectId="(0:0-230058267#573943946, 207)" Precode="3"><Text LanguageId="11274">I would not be deterred from prescribing if approved without a companion biomarker test</Text></Answer><Answer ObjectId="(0:0-230058268#573943951, 207)" Precode="4"><Text LanguageId="11274">I am unconvinced by the benefit of this agent, regardless of the availability of a companion biomarker test, and will not prescribe it</Text></Answer></Answers></Single><Info ObjectId="(0:0-230058283#573944004, 164)" Name="info1224"><Title LanguageId="11274">info1224</Title><Text LanguageId="11274">Please bear in mind that:

&lt;p&gt;We will be referring to unresectable or metastatic malignant melanoma only; we consider that the unresectable, first-line treatable malignant melanoma population equals the sum of the newly diagnosed incident cases of unresectable locally advanced (stage IIIA/B/C) and metastatic (stage IV) disease, plus all those patients diagnosed with earlier stages of disease who have clinically progressed to unresectable stage III and distant metastatic disease. &lt;/p&gt;</Text></Info><Page ObjectId="(0:0-230058297#573944048, 182)" Name="Copy of Page55"><Nodes><Info ObjectId="(0:0-230058299#573944054, 164)" Name="q53BM"><Title LanguageId="11274">q53BM</Title><Text LanguageId="11274">For what percentage of your unresectable or metastatic malignant melanoma patients do you currently send tumor tissue for testing for BRAF mutation?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction></Info><Open ObjectId="(0:0-230058310#573944083, 164)" Name="q53aBM"><Title LanguageId="11274">q53aBM</Title><Text LanguageId="11274">% of public patients</Text></Open><Open ObjectId="(0:0-230058322#573944115, 164)" Name="q53bBM"><Title LanguageId="11274">q53bBM</Title><Text LanguageId="11274">% of private patients</Text></Open></Nodes></Page><Grid3D ObjectId="(0:0-230058340#573944160, 204)" Name="q54aBM"><Title LanguageId="11274">q54aBM</Title><Text LanguageId="11274">When do you typically test your patients with malignant melanoma for BRAF mutation?</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230058384#611736598, 207)" Precode="1"><Text LanguageId="11274">At the time of diagnosis</Text></Answer><Answer ObjectId="(0:0-230058385#611736603, 207)" Precode="2"><Text LanguageId="11274">Before initiation of first-line unresectable or metastatic treatment</Text></Answer><Answer ObjectId="(0:0-230058386#611736608, 207)" Precode="3"><Text LanguageId="11274">After initiation of first-line unresectable or metastatic treatment but before second-line treatment</Text></Answer><Answer ObjectId="(0:0-230058387#611736613, 207)" Precode="4"><Text LanguageId="11274">After initiation of second-line unresectable or metastatic treatment but before third-line treatment</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230058342#573944165, 164)" Name="q54aBM_a"><Title LanguageId="11274">q54aBM_a</Title><Text LanguageId="11274">Public patients</Text></Single><Single ObjectId="(0:0-230058358#611736536, 164)" Name="q54aBM_b"><Title LanguageId="11274">q54aBM_b</Title><Text LanguageId="11274">Private patients</Text></Single></Nodes></Grid3D><Page ObjectId="(0:0-230058401#611736652, 182)" Name="Copy of Copy of Page55"><Nodes><Info ObjectId="(0:0-230058403#611736658, 164)" Name="q54bBM"><Title LanguageId="11274">q54bBM</Title><Text LanguageId="11274">For what percentage of all your unresectable or metastatic malignant melanoma patients whose tumor tissue is currently sent for molecular testing do you receive a conclusive test result?</Text><Instruction LanguageId="11274">Enter whole percentages.</Instruction></Info><Open ObjectId="(0:0-230058414#611736688, 164)" Name="q54bBM_a"><Title LanguageId="11274">q54bBM_a</Title><Text LanguageId="11274">Public patients</Text></Open><Open ObjectId="(0:0-230058426#611736721, 164)" Name="q54bBM_b"><Title LanguageId="11274">q54bBM_b</Title><Text LanguageId="11274">Private patients</Text></Open></Nodes></Page><Page ObjectId="(0:0-230058443#611736763, 182)" Name="Copy of Copy of Copy of Page55"><Nodes><Info ObjectId="(0:0-230058445#611736770, 164)" Name="q54cBM"><Title LanguageId="11274">q54cBM</Title><Text LanguageId="11274">What is the average time taken before you receive molecular test results?</Text><Instruction LanguageId="11274">Enter whole numbers of days.</Instruction></Info><Open ObjectId="(0:0-230058456#557091525, 164)" Name="q54cBM_a"><Title LanguageId="11274">q54cBM_a</Title><Text LanguageId="11274">Public patients</Text></Open><Open ObjectId="(0:0-230058468#557091558, 164)" Name="q54cBM_b"><Title LanguageId="11274">q54cBM_b</Title><Text LanguageId="11274">Private patients</Text></Open></Nodes></Page><Page ObjectId="(0:0-230058485#557091600, 182)" Name="Copy of Copy of Page63"><Nodes><Multi ObjectId="(0:0-230058487#557091606, 164)" Name="q55aBM"><Title LanguageId="11274">q55aBM</Title><Text LanguageId="11274">What most restricts your testing for BRAF mutation in Malignant Melanoma patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason OR select &quot;Nothing restricts testing, it is entirely my decision.&quot;</Instruction><Answers><Answer ObjectId="(0:0-230058497#557091648, 207)" Precode="1"><Text LanguageId="11274">Lack of coverage for the test</Text></Answer><Answer ObjectId="(0:0-230058498#557091653, 207)" Precode="2"><Text LanguageId="11274">Hospital/clinic restrict patient criteria for screening</Text></Answer><Answer ObjectId="(0:0-230058499#557091658, 207)" Precode="3"><Text LanguageId="11274">Patient out of pocket costs</Text></Answer><Answer ObjectId="(0:0-230058500#557091663, 207)" Precode="4"><Text LanguageId="11274">Access to testing facilities</Text></Answer><Answer ObjectId="(0:0-230058501#557091668, 207)" Precode="5"><Text LanguageId="11274">Need to treat before test results are available</Text></Answer><Answer ObjectId="(0:0-230058502#557091673, 207)" Precode="6"><Text LanguageId="11274">Lack of availability of tissue for testing/would require rebiopsy</Text></Answer><Answer ObjectId="(0:0-230058503#557091678, 207)" Precode="7"><Text LanguageId="11274">Restricted access to targeted drug (i.e. vemurafenib [Zelboraf])</Text></Answer><Answer ObjectId="(0:0-230058504#557091683, 207)" Precode="8"><Text LanguageId="11274">Molecular results does not impact my treatment decision</Text></Answer><Answer ObjectId="(0:0-230058505#557091688, 207)" Precode="9"><Text LanguageId="11274">Patient denies being tested</Text></Answer><Answer ObjectId="(0:0-230058506#557091693, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230058533#557091770, 164)" Name="q55bBM"><Title LanguageId="11274">q55bBM</Title><Answers><Answer ObjectId="(0:0-230058543#557091795, 207)" Precode="99"><Text LanguageId="11274">Nothing restricts testing, it is entirely my decision</Text></Answer></Answers></Multi></Nodes></Page><Page ObjectId="(0:0-230058557#557086970, 182)" Name="Copy of Copy of Copy of Page63"><Nodes><Grid3D ObjectId="(0:0-230058559#557086976, 204)" Name="q56BM"><Title LanguageId="11274">q56BM</Title><Text LanguageId="11274">What percentage of your drug-treated unresectable or metastatic BRAF+ malignant melanoma public patients, receives the following agents (+/- chemotherapy), per line of therapy?</Text><Instruction LanguageId="11274">Must sum to 100% OR select I do not prescribe drug-treatment for this line of therapy.</Instruction><Answers><Answer ObjectId="(0:0-230058709#557089413, 207)" Precode="1"><Text LanguageId="11274">Vemurafenib (Zelboraf)</Text></Answer><Answer ObjectId="(0:0-230058710#557089418, 207)" Precode="2"><Text LanguageId="11274">Ipilimumab (Yervoy)</Text></Answer><Answer ObjectId="(0:0-230058711#557089423, 207)" Precode="3"><Text LanguageId="11274">Immunotherapy excluding ipilimumab (e.g., Interferonalpha-2b, peginterferonalpha-2b, interleukin-2)</Text></Answer><Answer ObjectId="(0:0-230058712#557089428, 207)" Precode="4"><Text LanguageId="11274">Chemotherapy only</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230058561#557086981, 164)" Name="q56aBM"><Title LanguageId="11274">q56aBM</Title><Text LanguageId="11274">First-line</Text></Multi><Multi ObjectId="(0:0-230058607#557087139, 164)" Name="q56bBM"><Title LanguageId="11274">q56bBM</Title><Text LanguageId="11274">Second-line</Text></Multi><Multi ObjectId="(0:0-230058653#557089213, 164)" Name="q56cBM"><Title LanguageId="11274">q56cBM</Title><Text LanguageId="11274">Third-line</Text></Multi></Nodes></Grid3D><Multi ObjectId="(0:0-230058726#557089466, 164)" Name="q56bBM_NA"><Title LanguageId="11274">q56bBM_NA</Title><Text LanguageId="11274">Second-line</Text><Answers><Answer ObjectId="(0:0-230058736#557089492, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230058745#557086389, 164)" Name="q56cBM_NA"><Title LanguageId="11274">q56cBM_NA</Title><Text LanguageId="11274">Third-line</Text><Answers><Answer ObjectId="(0:0-230058755#557086415, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers></Multi></Nodes></Page><Page ObjectId="(0:0-230058769#557086445, 182)" Name="Copy of Copy of Copy of Copy of Page63"><Nodes><Grid3D ObjectId="(0:0-230058771#557086451, 204)" Name="q57BM"><Title LanguageId="11274">q57BM</Title><Text LanguageId="11274">What percentage of your drug-treated unresectable or metastatic BRAF+ malignant melanoma private patients, receives the following agents (+/- chemotherapy), per line of therapy?</Text><Instruction LanguageId="11274">Must sum to 100% OR select I do not prescribe drug-treatment for this line of therapy.</Instruction><Answers><Answer ObjectId="(0:0-230058921#535745185, 207)" Precode="1"><Text LanguageId="11274">Vemurafenib (Zelboraf)</Text></Answer><Answer ObjectId="(0:0-230058922#535745190, 207)" Precode="2"><Text LanguageId="11274">Ipilimumab (Yervoy)</Text></Answer><Answer ObjectId="(0:0-230058923#535745195, 207)" Precode="3"><Text LanguageId="11274">Immunotherapy excluding ipilimumab (e.g., Interferonalpha-2b, peginterferonalpha-2b, interleukin-2)</Text></Answer><Answer ObjectId="(0:0-230058924#535745200, 207)" Precode="4"><Text LanguageId="11274">Chemotherapy only</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230058773#557086456, 164)" Name="q57aBM"><Title LanguageId="11274">q57aBM</Title><Text LanguageId="11274">First-line</Text></Multi><Multi ObjectId="(0:0-230058819#557086614, 164)" Name="q57bBM"><Title LanguageId="11274">q57bBM</Title><Text LanguageId="11274">Second-line</Text></Multi><Multi ObjectId="(0:0-230058865#535744985, 164)" Name="q57cBM"><Title LanguageId="11274">q57cBM</Title><Text LanguageId="11274">Third-line</Text></Multi></Nodes></Grid3D><Multi ObjectId="(0:0-230058938#535745238, 164)" Name="q57bBM_NA"><Title LanguageId="11274">q57bBM_NA</Title><Text LanguageId="11274">Second-line</Text><Answers><Answer ObjectId="(0:0-230058948#535745264, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230058957#574778691, 164)" Name="q57cBM_NA"><Title LanguageId="11274">q57cBM_NA</Title><Text LanguageId="11274">Third-line</Text><Answers><Answer ObjectId="(0:0-230058967#574778717, 207)" Precode="99"><Text LanguageId="11274">I do not prescribe drug-treatment for this line of therapy</Text></Answer></Answers></Multi></Nodes></Page><Grid3D ObjectId="(0:0-230058978#574778742, 204)" Name="q58BM"><Title LanguageId="11274">q58BM</Title><Text LanguageId="11274">If all of the following treatments were approved by the regulatory agencies in your country and 100% funded/covered/ reimbursed for unresectable or metastatic BRAF+ malignant melanoma by the patient’s health insurance plan and/or by the government or ^f('Sq1').get() == '1' ? &quot;Social Security&quot; : &quot;the Obras Sociales&quot;^, which one would you primarily consider prescribing to your patients (+/- chemotherapy)?

&lt;script type=&quot;text/javascript&quot;&gt;
window.onload = function()
{

if(document.getElementById(&quot;q58aBM_99&quot;) != null)
document.getElementById(&quot;q58aBM_99&quot;).disabled = true;

}
&lt;/script&gt;</Text><Instruction LanguageId="11274">Select one per column.</Instruction><Answers><Answer ObjectId="(0:0-230059038#574778903, 207)" Precode="1"><Text LanguageId="11274">Vemurafenib (Zelboraf)</Text></Answer><Answer ObjectId="(0:0-230059039#574778908, 207)" Precode="2"><Text LanguageId="11274">Ipilimumab (Yervoy)</Text></Answer><Answer ObjectId="(0:0-230059040#574778913, 207)" Precode="3"><Text LanguageId="11274">Immunotherapy excluding ipilimumab (e.g., Interferonalpha-2b, peginterferonalpha-2b, interleukin-2)</Text></Answer><Answer ObjectId="(0:0-230059041#574778918, 207)" Precode="4"><Text LanguageId="11274">No targeted agent (chemotherapy only)</Text></Answer><Answer ObjectId="(0:0-230059042#574778923, 207)" Precode="99"><Text LanguageId="11274">I would not prescribe drug-treatment for this line of therapy</Text></Answer></Answers><Nodes><Single ObjectId="(0:0-230058980#574778749, 164)" Name="q58aBM"><Title LanguageId="11274">q58aBM</Title><Text LanguageId="11274">First-line</Text></Single><Single ObjectId="(0:0-230058996#574778793, 164)" Name="q58bBM"><Title LanguageId="11274">q58bBM</Title><Text LanguageId="11274">Second-line</Text></Single><Single ObjectId="(0:0-230059012#574778828, 164)" Name="q58cBM"><Title LanguageId="11274">q58cBM</Title><Text LanguageId="11274">Third-line</Text></Single></Nodes></Grid3D><Info ObjectId="(0:0-230059058#611778035, 164)" Name="MMAgents"><Title LanguageId="11274">MMAgents</Title><Text LanguageId="11274">&lt;P style=&quot;MARGIN: 0in 0in 8pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;U&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 107%; FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Emerging Agents for unresectable/metastatic malignant melanoma 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;MARGIN: 0in 0in 8pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 107%; FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 8.0pt; mso-ansi-language: en-us&quot;&gt;Dabrafenib (&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;Tafinlar&lt;/B&gt;) and trametinib (&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;Mekinist&lt;/B&gt;) were launched in the US and in Europe in 2013 for the treatment of &lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;unresectable/metastatic BRAF+ malignant melanoma&lt;/B&gt;, and they are expected to launch in your country in 2014/2015:&lt;/SPAN&gt;&lt;U&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 107%; FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/U&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE style=&quot;BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; MARGIN: auto auto auto 13.95pt; BORDER-COLLAPSE: collapse; BORDER-TOP: medium none; BORDER-RIGHT: medium none; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-alt: solid black .5pt; mso-border-insideh: .5pt solid black; mso-border-insidev: .5pt solid black; mso-table-layout-alt: fixed&quot; class=MsoNormalTable border=1 cellSpacing=0 cellPadding=0 width=529&gt;
&lt;TBODY&gt;
&lt;TR style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 77.95pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt&quot; vAlign=top width=104&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;
&lt;P&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt&quot; width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Tafinlar (GlaxoSmithKline’s dabrafenib) &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;(BRAF inhibitor)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 106.35pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Mekinist (GlaxoSmithKline’s trametinib)&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style=&quot;mso-ansi-language: en-us&quot;&gt;&lt;FONT size=3 face=Calibri&gt; &lt;/FONT&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;(MEK1/2 inhibitor)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Tafinlar and Mekinist in combination&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;mso-yfti-irow: 1&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 77.95pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=104&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Dosing&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;150 mg (oral), twice daily&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.35pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;2 mg (oral), once daily&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal align=center&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;-&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;mso-yfti-irow: 2&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 77.95pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=104&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Development status&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Phase III; one completed clinical trial in Argentina (none in Mexico)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.35pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Phase III; two completed clinical trials in Argentina (none in Mexico)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Phase III; two completed clinical trials in Argentina (none in Mexico). Approved in January 2014 by the FDA.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;HEIGHT: 49.6pt; mso-yfti-irow: 3&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 77.95pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; HEIGHT: 49.6pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=104&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Phase III trials 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;
&lt;P&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; HEIGHT: 49.6pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;BREAK-3 trial: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Tafinlar vs. dacarbazine in BRAF-V600E-mutation positive, treatment-naive patients 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1&quot; class=MsoListParagraphCxSpFirst&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Improvement in PFS (6.9 vs 2.7 months; P &lt; 0.0001; hazard ratio 0.37)&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/B&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Improved ORR (50% vs 6%) 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1&quot; class=MsoListParagraphCxSpLast&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Increased OS (18.2 vs 15.6 months; hazard ratio 0.76)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.35pt; PADDING-RIGHT: 5.4pt; HEIGHT: 49.6pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;METRIC trial: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Mekinist vs. chemotherapy (dacarbazine or paclitaxel) in V660E or V600K BRAF mutations, first-line 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=MsoListParagraphCxSpFirst&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Significant improvement in PFS (4.8 vs 1.5 months; P &lt; 0.001) 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Improved ORR (22% vs 8%) 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=MsoListParagraphCxSpLast&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;A six-month OS advantage was observed (81% vs 67%)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; HEIGHT: 49.6pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;COMBI-d trial: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Tafinlar/Mekinist vs.Tafinlar in BRAF V600E or V600K mutation positive patients; M1a (11%), M1b (19%), M1c (70%), no prior BRAF- or MEK inhibitors 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=MsoListParagraphCxSpFirst&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Improvement in PFS (9.4 vs 5.8 months) 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=MsoListParagraphCxSpMiddle&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Improved ORR (76% vs 54%) 
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l1 level1 lfo2&quot; class=MsoListParagraphCxSpLast&gt;&lt;SPAN style=&quot;FONT-FAMILY: symbol; FONT-SIZE: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;SPAN style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;SPAN style=&quot;FONT: 7pt 'times new roman'&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt&quot;&gt;Increased OS (23.8 vs 20.2 months)&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style=&quot;HEIGHT: 56.45pt; mso-yfti-irow: 4; mso-yfti-lastrow: yes&quot;&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-LEFT: 5.4pt; WIDTH: 77.95pt; PADDING-RIGHT: 5.4pt; BACKGROUND: #c6d9f1; HEIGHT: 56.45pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=104&gt;
&lt;P style=&quot;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt&quot; class=MsoNormal&gt;&lt;B style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;SPAN style=&quot;FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: en-us&quot;&gt;Most common grade 3/4 adverse events&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; HEIGHT: 56.45pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: 115%; MARGIN: 0in 0in 8pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 115%; FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 9.0pt; mso-ansi-language: en-us&quot;&gt;Squamous-cell carcinoma: 4%; pyrexia: 3%; PPE: 2%.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.35pt; PADDING-RIGHT: 5.4pt; HEIGHT: 56.45pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: 115%; MARGIN: 0in 0in 8pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 115%; FONT-FAMILY: 'arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 9.0pt&quot; lang=PT&gt;Hypertension: 12%; &lt;/SPAN&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 115%; FONT-FAMILY: 'arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-size: 9.0pt; mso-fareast-font-family: 'times new roman'&quot; lang=PT&gt;rash: 8%; fatigue: 4%&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style=&quot;BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 106.3pt; PADDING-RIGHT: 5.4pt; HEIGHT: 56.45pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0in; mso-border-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; vAlign=top width=142&gt;
&lt;P style=&quot;LINE-HEIGHT: 115%; MARGIN: 0in 0in 8pt&quot; class=MsoNormal&gt;&lt;SPAN style=&quot;LINE-HEIGHT: 115%; FONT-FAMILY: 'arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-size: 9.0pt; mso-ansi-language: en-us; mso-fareast-font-family: 'times new roman'&quot;&gt;Pyrexia: 9%; nausea: 6%; elevated blood alkaline phosphatase: 6%; vomiting: 4%.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;</Text></Info><Page ObjectId="(0:0-230059072#611778705, 182)" Name="Page56"><Nodes><Grid3D ObjectId="(0:0-230059074#611778711, 204)" Name="q59BM"><Title LanguageId="11274">q59BM</Title><Text LanguageId="11274">Which of the following statements do you agree with when considering prescribing Tafinlar and/or Mekinist in first-line of therapy to BRAF+ unresectable/metastatic malignant melanoma patients, by the end of 2017, assuming these treatments are approved and launched in your country?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230059134#611778857, 207)" Precode="1"><Text LanguageId="11274">Greater efficacy</Text></Answer><Answer ObjectId="(0:0-230059135#611778862, 207)" Precode="2"><Text LanguageId="11274">Reduced toxicity</Text></Answer><Answer ObjectId="(0:0-230059136#611778867, 207)" Precode="3"><Text LanguageId="11274">Improved tolerability</Text></Answer><Answer ObjectId="(0:0-230059137#611778872, 207)" Precode="4"><Text LanguageId="11274">I prefer to prescribe oral agents over IV agents (e.g., ipilimumab)</Text></Answer><Answer ObjectId="(0:0-230059138#611778877, 207)" Precode="5"><Text LanguageId="11274">Other</Text></Answer><Answer ObjectId="(0:0-230059139#611778882, 207)" Precode="6"><Text LanguageId="11274">I anticipate a favorable environment for inclusion in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230059140#611778887, 207)" Precode="7"><Text LanguageId="11274">I anticipate a favorable environment for inclusion in the private sector hospital/institutional formularies</Text></Answer><Answer ObjectId="(0:0-230059141#611778892, 207)" Precode="99"><Text LanguageId="11274">I do not predict to prescribe this agent/combination</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230059076#611778719, 164)" Name="q59aBM"><Title LanguageId="11274">q59aBM</Title><Text LanguageId="11274">Tafinlar</Text></Multi><Multi ObjectId="(0:0-230059092#611778754, 164)" Name="q59bBM"><Title LanguageId="11274">q59bBM</Title><Text LanguageId="11274">Mekinist</Text></Multi><Multi ObjectId="(0:0-230059108#611778789, 164)" Name="q59cBM"><Title LanguageId="11274">q59cBM</Title><Text LanguageId="11274">Tafinlar&lt;br&gt;/Mekinist</Text></Multi></Nodes></Grid3D><Open ObjectId="(0:0-230059163#573944202, 164)" Name="q59aBM_Other"><Title LanguageId="11274">q59aBM_Other</Title><Text LanguageId="11274">Please specify the Other for Tafinlar.</Text></Open><Open ObjectId="(0:0-230059175#573944232, 164)" Name="q59bBM_Other"><Title LanguageId="11274">q59bBM_Other</Title><Text LanguageId="11274">Please specify the Other for Mekinist.</Text></Open><Open ObjectId="(0:0-230059187#573944262, 164)" Name="q59cBM_Other"><Title LanguageId="11274">q59cBM_Other</Title><Text LanguageId="11274">Please specify the Other for Tafinlar/Mekinist.</Text></Open></Nodes></Page><Page ObjectId="(0:0-230059207#573944315, 182)" Name="Copy of Page56"><Nodes><Grid3D ObjectId="(0:0-230059209#573944320, 204)" Name="q60BM"><Title LanguageId="11274">q60BM</Title><Text LanguageId="11274">Why do you not expect to prescribe Tafinlar and/or Mekinist in first-line of therapy to BRAF+ unresectable/metastatic malignant melanoma patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason, etc.</Instruction><Answers><Answer ObjectId="(0:0-230059269#557080667, 207)" Precode="1"><Text LanguageId="11274">There are more efficacious therapies in all lines of treatment</Text></Answer><Answer ObjectId="(0:0-230059270#557080672, 207)" Precode="2"><Text LanguageId="11274">I believe that ipilimumab (Yervoy) offers a more durable benefit in the first-line setting, so I would rather prescribe this agent in second-line of therapy</Text></Answer><Answer ObjectId="(0:0-230059271#557080677, 207)" Precode="3"><Text LanguageId="11274">I believe that the sooner uptake of vemurafenif (Zelboraf) will restrain the usage of this agent</Text></Answer><Answer ObjectId="(0:0-230059272#557080682, 207)" Precode="4"><Text LanguageId="11274">I have concerns over the toxicity profile</Text></Answer><Answer ObjectId="(0:0-230059273#557080687, 207)" Precode="5"><Text LanguageId="11274">I anticipate lack of coverage for the molecular test</Text></Answer><Answer ObjectId="(0:0-230059274#557080692, 207)" Precode="6"><Text LanguageId="11274">I do not think that this treatment will be included in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230059275#557080697, 207)" Precode="7"><Text LanguageId="11274">I do not think that this treatment will be covered in private hospitasl/institutions</Text></Answer><Answer ObjectId="(0:0-230059276#557080702, 207)" Precode="8"><Text LanguageId="11274">I do not expect BRAF mutation test results to be covered before initiation of first-line treatment</Text></Answer><Answer ObjectId="(0:0-230059277#557080707, 207)" Precode="9"><Text LanguageId="11274">Higher overall cost of treatment will certainly restrict coverage</Text></Answer><Answer ObjectId="(0:0-230059278#557080712, 207)" Precode="98"><Text LanguageId="11274">Other</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230059211#573944325, 164)" Name="q60aBM"><Title LanguageId="11274">q60aBM</Title><Text LanguageId="11274">Tafinlar</Text></Multi><Multi ObjectId="(0:0-230059227#573944365, 164)" Name="q60bBM"><Title LanguageId="11274">q60bBM</Title><Text LanguageId="11274">Mekinist</Text></Multi><Multi ObjectId="(0:0-230059243#573944405, 164)" Name="q60cBM"><Title LanguageId="11274">q60cBM</Title><Text LanguageId="11274">Tafinlar&lt;br&gt;/Mekinist</Text></Multi></Nodes></Grid3D><Open ObjectId="(0:0-230059304#557080791, 164)" Name="q60aBM_Other"><Title LanguageId="11274">q60aBM_Other</Title><Text LanguageId="11274">Please specify the Other for Tafinlar.</Text></Open><Open ObjectId="(0:0-230059316#557080821, 164)" Name="q60bBM_Other"><Title LanguageId="11274">q60bBM_Other</Title><Text LanguageId="11274">Please specify the Other for Mekinist.</Text></Open><Open ObjectId="(0:0-230059328#557080851, 164)" Name="q60cBM_Other"><Title LanguageId="11274">q60cBM_Other</Title><Text LanguageId="11274">Please specify the Other for Tafinlar/Mekinist.</Text></Open></Nodes></Page><Grid3D ObjectId="(0:0-230059348#557082421, 204)" Name="q61BM"><Title LanguageId="11274">q61BM</Title><Text LanguageId="11274">Please estimate what proportion of your first-line drug-treated unresectable or metastatic BRAF+ malignant melanoma patients will be receiving each indicated therapy, by the end of 2017.</Text><Instruction LanguageId="11274">Must sum to 100%. For your reference, the percentages you estimated for your current use of these treatments are shown below.  Please bear in mind:
&lt;p&gt;A.	The expected launch of dabrafenib and trametinib;
&lt;p&gt;B.	Your own clinical experience and preferences, but also your knowledge of the reimbursement/funding situation in your hospital, region or country.</Instruction><Answers><Answer ObjectId="(0:0-230059424#557082625, 207)" Precode="1"><Text LanguageId="11274">Vemurafenib (Zelboraf)</Text></Answer><Answer ObjectId="(0:0-230059425#557082630, 207)" Precode="2"><Text LanguageId="11274">Ipilimumab (Yervoy)</Text></Answer><Answer ObjectId="(0:0-230059426#557082635, 207)" Precode="3"><Text LanguageId="11274">Immunotherapy excluding ipilimumab (e.g., Interferonalpha-2b, peginterferonalpha-2b, interleukin-2)</Text></Answer><Answer ObjectId="(0:0-230059427#557082640, 207)" Precode="4"><Text LanguageId="11274">Dabrafenib (Tafinlar)</Text></Answer><Answer ObjectId="(0:0-230059428#557082645, 207)" Precode="5"><Text LanguageId="11274">Trametinib (Mekinist)</Text></Answer><Answer ObjectId="(0:0-230059429#557082650, 207)" Precode="6"><Text LanguageId="11274">Dabrafenib (Tafinlar)+ Trametinib (Mekinist) in combination</Text></Answer><Answer ObjectId="(0:0-230059430#557082655, 207)" Precode="7"><Text LanguageId="11274">No targeted agent (chemotherapy only)</Text></Answer></Answers><Nodes><Multi ObjectId="(0:0-230059350#557082429, 164)" Name="q61aBM"><Title LanguageId="11274">q61aBM</Title><Text LanguageId="11274">% of public patients - Current</Text></Multi><Multi ObjectId="(0:0-230059366#557082471, 164)" Name="q61bBM"><Title LanguageId="11274">q61bBM</Title><Text LanguageId="11274">% of public patients - 2017</Text></Multi><Multi ObjectId="(0:0-230059382#557082513, 164)" Name="q61cBM"><Title LanguageId="11274">q61cBM</Title><Text LanguageId="11274">% of private patients - Current</Text></Multi><Multi ObjectId="(0:0-230059398#557082555, 164)" Name="q61dBM"><Title LanguageId="11274">q61dBM</Title><Text LanguageId="11274">% of private patients - 2017</Text></Multi></Nodes></Grid3D><Info ObjectId="(0:0-230059450#611778951, 164)" Name="Binimetinib"><Title LanguageId="11274">Binimetinib</Title><Text LanguageId="11274">&lt;p style=&quot;margin: 0in 0in 10pt 10.9pt; mso-add-space: auto; tab-stops: 145.5pt&quot; class=&quot;MsoListParagraph&quot;&gt;&lt;span style=&quot;line-height: 115%; font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-bidi-font-size: 11.0pt&quot;&gt;Binimetinib (Novartis’s MEK-162) is being evaluated as a monotherapy in melanoma patients with a &lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;NRAS&lt;/b&gt; mutation: &lt;span style=&quot;mso-spacerun: yes&quot;&gt;&#160;&lt;/span&gt;&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;table style=&quot;border-bottom: medium none; border-left: medium none; margin: auto auto auto 13.95pt; width: 382.7pt; border-collapse: collapse; border-top: medium none; border-right: medium none; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-border-alt: solid black .5pt; mso-border-insideh: .5pt solid black; mso-border-insidev: .5pt solid black&quot; class=&quot;MsoNormalTable&quot; border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;510&quot;&gt;&lt;tbody&gt;&lt;tr style=&quot;mso-yfti-irow: 0; mso-yfti-firstrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 382.7pt; padding-right: 5.4pt; background: #c6d9f1; border-top: black 1pt solid; border-right: black 1pt solid; padding-top: 0in; mso-border-alt: solid black .5pt&quot; width=&quot;510&quot;&gt;&lt;p style=&quot;line-height: normal; margin: 0in 0in 0pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Binimetinib (Novartis’s MEK-162) &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;(MEK 1 and 2 inhibitor)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=&quot;height: 176.9pt; mso-yfti-irow: 1; mso-yfti-lastrow: yes&quot;&gt;&lt;td style=&quot;border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0in; background-color: transparent; padding-left: 5.4pt; width: 382.7pt; padding-right: 5.4pt; height: 176.9pt; border-top: #f0f0f0; border-right: black 1pt solid; padding-top: 0in; mso-border-alt: solid black .5pt; mso-border-top-alt: solid black .5pt&quot; valign=&quot;top&quot; width=&quot;510&quot;&gt;&lt;p style=&quot;text-align: justify; line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Development status: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;one ongoing Phase III trial (Argentina included)&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;u&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;&lt;p&gt;&lt;span style=&quot;text-decoration: none&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;text-decoration: none&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;u&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Data of a 3-arm Phase II trial: &lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1; tab-stops: 239.75pt&quot; class=&quot;MsoListParagraphCxSpFirst&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: arial&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;1)&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;NRAS mutated &lt;/span&gt;&lt;span style=&quot;font-family: wingdings; font-size: 9pt; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: timesnewromanpsmt; mso-bidi-font-family: arial; mso-ascii-font-family: arial; mso-hansi-font-family: arial; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;span style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 9pt; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: timesnewromanpsmt; mso-fareast-language: en-gb&quot;&gt; &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;45 mg twice daily&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.75in; mso-add-space: auto; mso-list: l1 level1 lfo2; tab-stops: 239.75pt&quot; class=&quot;MsoListParagraphCxSpMiddle&quot;&gt;&lt;span style=&quot;font-family: symbol; font-size: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;6 of 30 patients (20%) experienced a PR (only 3 confirmed)&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1; tab-stops: 239.75pt&quot; class=&quot;MsoListParagraphCxSpMiddle&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: arial&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;2)&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;BRAF-mutated &lt;/span&gt;&lt;span style=&quot;font-family: wingdings; font-size: 9pt; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: timesnewromanpsmt; mso-bidi-font-family: arial; mso-ascii-font-family: arial; mso-hansi-font-family: arial; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;span style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 9pt; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: timesnewromanpsmt; mso-fareast-language: en-gb&quot;&gt; &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;45 mg twice daily &lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.25in; mso-add-space: auto; mso-list: l0 level1 lfo1; tab-stops: 239.75pt&quot; class=&quot;MsoListParagraphCxSpMiddle&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-fareast-font-family: arial&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;3)&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;BRAF-mutated &lt;/span&gt;&lt;span style=&quot;font-family: wingdings; font-size: 9pt; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: timesnewromanpsmt; mso-bidi-font-family: arial; mso-ascii-font-family: arial; mso-hansi-font-family: arial; mso-fareast-language: en-gb; mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&lt;span style=&quot;mso-char-type: symbol; mso-symbol-font-family: wingdings&quot;&gt;&#224;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 9pt; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: timesnewromanpsmt; mso-fareast-language: en-gb&quot;&gt; &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;60 mg twice daily&lt;p&gt;&lt;/p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; text-indent: -0.25in; margin: 0in 0in 0pt 0.75in; mso-add-space: auto; mso-list: l1 level1 lfo2; tab-stops: 239.75pt&quot; class=&quot;MsoListParagraphCxSpLast&quot;&gt;&lt;span style=&quot;font-family: symbol; font-size: 10pt; mso-fareast-font-family: symbol; mso-bidi-font-family: symbol&quot;&gt;&lt;span style=&quot;mso-list: ignore&quot;&gt;&#183;&lt;span style=&quot;font: 7pt &amp;quot;times new roman&amp;quot;&quot;&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt&quot;&gt;8 of 41 patients (also 20%) had a PR (only 2 confirmed)&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Side effects:&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us; mso-bidi-font-size: 11.0pt&quot;&gt; &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;acneiform dermatitis (60% and 37%), rash (20% and 39%), peripheral edema (33% and 34%), diarrhea (27% and 37%), and creatine phosphokinase increases (37% and 22%) in patients with NRAS-mutated melanoma and BRAF-mutated melanoma, respectively. Increased creatine phosphokinase was the most common grade 3/4 AE (23% and 17%).&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p style=&quot;text-align: justify; line-height: normal; margin: 0in 0in 0pt; tab-stops: 239.75pt&quot; class=&quot;MsoNormal&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight: normal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt; mso-ansi-language: en-us&quot;&gt;Estimated launch date: 2016&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</Text></Info><Multi ObjectId="(0:0-230059464#611779291, 164)" Name="q62BM"><Title LanguageId="11274">q62BM</Title><Text LanguageId="11274">Which of the following statements do you agree with when considering prescribing binimetinib to NRAS-mutation-positive melanoma, by the end of 2017, assuming this treatment is approved and launched in your country?</Text><Instruction LanguageId="11274">Select all that apply.</Instruction><Answers><Answer ObjectId="(0:0-230059474#611779320, 207)" Precode="1"><Text LanguageId="11274">Greater efficacy</Text></Answer><Answer ObjectId="(0:0-230059475#611779325, 207)" Precode="2"><Text LanguageId="11274">Possibility of targeting a better defined population</Text></Answer><Answer ObjectId="(0:0-230059476#611779330, 207)" Precode="3"><Text LanguageId="11274">Reduced toxicity</Text></Answer><Answer ObjectId="(0:0-230059477#611779335, 207)" Precode="4"><Text LanguageId="11274">Future possibility for usage in combination with other targeted agents</Text></Answer><Answer ObjectId="(0:0-230059478#611779340, 207)" Precode="5"><Text LanguageId="11274">Other (please specify)</Text></Answer><Answer ObjectId="(0:0-230059479#611779345, 207)" Precode="6"><Text LanguageId="11274">I anticipate a favorable environment for inclusion in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230059480#611779350, 207)" Precode="7"><Text LanguageId="11274">I anticipate a favorable environment for inclusion in the private sector hospital/institutional formularies</Text></Answer><Answer ObjectId="(0:0-230059481#611779355, 207)" Precode="99"><Text LanguageId="11274">I do not predict to prescribe this agent</Text></Answer></Answers></Multi><Multi ObjectId="(0:0-230059510#611779442, 164)" Name="q63BM"><Title LanguageId="11274">q63BM</Title><Text LanguageId="11274">Why do you not expect to prescribe binimetinib to your NRAS mutation-positive unresectable/metastatic malignant melanoma patients?</Text><Instruction LanguageId="11274">Rank up to three reasons where 1 = primary reason, etc.</Instruction><Answers><Answer ObjectId="(0:0-230059520#611779473, 207)" Precode="1"><Text LanguageId="11274">Insufficient data on greater efficacy over other treatments</Text></Answer><Answer ObjectId="(0:0-230059521#611779478, 207)" Precode="2"><Text LanguageId="11274">I believe that ipilimumab (Yervoy) offers a more durable benefit in the first-line setting, so I would rather prescribe this agent in second-line of therapy</Text></Answer><Answer ObjectId="(0:0-230059522#611779483, 207)" Precode="3"><Text LanguageId="11274">I have some concerns regarding the toxicity profile of this drug</Text></Answer><Answer ObjectId="(0:0-230059523#611779488, 207)" Precode="4"><Text LanguageId="11274">I expect coverage restrictions to limit prescribing of this therapy</Text></Answer><Answer ObjectId="(0:0-230059524#611779493, 207)" Precode="5"><Text LanguageId="11274">Requirement for treatment before mutation test results are known</Text></Answer><Answer ObjectId="(0:0-230059525#611779498, 207)" Precode="6"><Text LanguageId="11274">I do not expect mutation test results to be covered</Text></Answer><Answer ObjectId="(0:0-230059526#611779503, 207)" Precode="7"><Text LanguageId="11274">I do not think that this treatment will be included in the national/institutional coverage formularies</Text></Answer><Answer ObjectId="(0:0-230059527#611779508, 207)" Precode="8"><Text LanguageId="11274">I do not think that this treatment will be covered in private hospitals/institutions</Text></Answer><Answer ObjectId="(0:0-230059528#611779513, 207)" Precode="98"><Text LanguageId="11274">Other (please specify)</Text></Answer></Answers></Multi><Single ObjectId="(0:0-230059556#578252365, 164)" Name="q64BM"><Title LanguageId="11274">q64BM</Title><Text LanguageId="11274">How easy will it be to incorporate NRAS testing in your routine practice?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230059566#578252392, 207)" Precode="1"><Text LanguageId="11274">Very easy, I consider testing for NRAS mutation as important as testing for BRAF mutation and I do not predict coverage/funding restrictions for binimetinib upon NRAS testing</Text></Answer><Answer ObjectId="(0:0-230059567#578252397, 207)" Precode="2"><Text LanguageId="11274">Easy, I do not predict coverage/funding restrictions for binimetinib upon NRAS testing, but I only predict to test for NRAS mutation a sub-population (e.g., patients tested for BRAF whose results were negative)</Text></Answer><Answer ObjectId="(0:0-230059568#578252402, 207)" Precode="3"><Text LanguageId="11274">Not easy, I predict that the difficulty in defining a sub-population for the test will raise coverage/funding restrictions for binimetinib</Text></Answer><Answer ObjectId="(0:0-230059569#578252407, 207)" Precode="4"><Text LanguageId="11274">Very difficult, I expect severe coverage/funding restrictions for binimetinib upon NRAS testing in any condition</Text></Answer></Answers></Single><Single ObjectId="(0:0-230059584#578252461, 164)" Name="q64aBM"><Title LanguageId="11274">q64aBM</Title><Text LanguageId="11274">How widely available are NRAS mutation tests currently in your country?</Text><Instruction LanguageId="11274">Select one.</Instruction><Answers><Answer ObjectId="(0:0-230059594#578252487, 207)" Precode="1"><Text LanguageId="11274">Widely available, with many testing sites throughout the country equipped with the technology</Text></Answer><Answer ObjectId="(0:0-230059595#578252492, 207)" Precode="2"><Text LanguageId="11274">Somewhat available, with some remote testing sites outside the major cities/hospitals</Text></Answer><Answer ObjectId="(0:0-230059596#578252497, 207)" Precode="3"><Text LanguageId="11274">Somewhat unavailable, with testing sites only availably in the major cities/hospitals</Text></Answer><Answer ObjectId="(0:0-230059597#578252502, 207)" Precode="4"><Text LanguageId="11274">Widely unavailable, with almost no testing sites in my country</Text></Answer></Answers></Single></Nodes></Folder><Folder ObjectId="(0:0-230059614#578252551, 198)" Name="Stop-Complete WorldOne"><Nodes></Nodes></Folder></Routing></Survey>
